



*National Institute of Dental and Craniofacial Research  
Division of Intramural Research*

# ANNUAL REPORT SUMMARY

# 1998



Fiscal Year 1998 Annual Report  
National Institute of Dental and Craniofacial Research

Introduction and Overview	1
Craniofacial Developmental Biology and Regeneration Branch	5
Craniofacial and Skeletal Diseases Branch	16
Gene Therapy and Therapeutics Branch	24
Oral Health Promotion, Risk Factors, and Molecular Epidemiology Branch	32
Oral Infection and Immunity Branch	37
Oral and Pharyngeal Cancer Branch	49
Pain and Neurosensory Mechanisms Branch	56
Functional Genomics Unit	63
Immunopathology Section	65
Matrix Metalloproteinase Unit	67
Molecular Structural Biology Unit	69



# INTRODUCTION AND OVERVIEW

*Henning Birkedal-Hansen, Scientific Director*



# **THE DIVISION OF INTRAMURAL RESEARCH**

## **ANNUAL REPORT 1998**

### **INTRODUCTION AND OVERVIEW**

The National Institute of Dental and Craniofacial Research witnessed several major changes in FY98. The Institute changed its name (formerly the National Institute of Dental Research) to more accurately reflect its continuously evolving mission and also in the same period celebrated its 50<sup>th</sup> anniversary. Since the NIDCR was originally entirely intramural, FY98 also marked the 50<sup>th</sup> anniversary of the Institute's in-house research program. The Division helped celebrate this monumental milestone in many ways. It co-organized two major scientific symposia, one at the American Association of Dental Research Annual Meeting in Minneapolis, MN (March, 1998), and another at the Natcher Conference Center, NIH in Bethesda, MD (June, 1998). A brief account of the history and highlights of the "first fifty years" was published in the Journal of the American Dental Association (Birkedal-Hansen, H.: JADA 129, 702-710, 1998).

#### **Continuing Reorganization and Restructuring**

Pursuant to the reorganization plan for the intramural research programs initiated in FY97, a number of additional steps were taken to align the structure and function of the DIR to more closely reflect the letter and the spirit of the NIDCR Strategic Plan as detailed below.

The Division reaffirmed its commitment to empowerment of independent Senior Investigators (SIs) by flattening the Branch structure and by adopting an annually negotiated SI-based resource allocation process. The ultimate goal, which will be achieved in FY2000, is a fully implemented project- (rather than investigator-) based budget negotiation process, resource allocation process and annual progress report process. For the first time, this establishes a direct link between resource allocation and scientific project progress as detailed in the annual report.

The reorganization of the Oral Health Promotion, Risk Factors and Molecular Epidemiology Branch (OHPRFMEB) is continuing. The Health Program Section was moved to the Office of the Director. In addition, the conduct and management of national surveys is being transferred to the Office of the Director. To provide for a seamless transfer and to assist with the preparation of the Surgeon General's Report on Oral Health, Dr. Deborah Winn was unofficially "detailed" for one year to the Office of the Director. Dr. Henning Birkedal-Hansen served as Acting Branch Chief, while Dr. Scott Diehl served as Deputy Acting Branch Chief and managed the Branch on a daily basis. As a consequence of the progressive reorganization of OHPRFMEB and the needs of the Institute, an NIDCR Biostatistics Core Facility was established to provide expert consult on biostatistics, experimental design, data management, analysis, and related services. Dr. Albert Kingman, NIDCR Chief Statistician, was appointed Core Director. Organizationally, the Core represents an entirely new concept as it straddles all Divisions/Offices within the organization without definitive boundaries.

The Division funded a second round of "Emerging Opportunities" proposals aimed at providing support for particularly novel and imaginative research ideas. An ad hoc group of outside experts reviewed all proposals and identified the most meritorious, which were subsequently funded.



The program has been quite successful in providing financial support for particularly innovative science, and has as such fully served the purpose for which it was intended.

In recognition of his many important contributions to the leadership of the Division, Dr. Jack London was named Assistant Scientific Director. In addition to his role in daily divisional leadership functions, Dr. London has assumed responsibility for issues related to space, the research core facilities, and advisory committees.

### **Trans-NIH Initiatives**

Areas of interest shared widely on campus, such as Pain, Head and Neck Cancer, and Skeletal Diseases, increasingly have become the foci for efforts to build campus-wide, multi-institute programs and initiatives. (i) The NIDCR, in partnership with NINDS, conducted a two-day “Pain Research Think Tank” aimed at considering the feasibility of and mechanisms for establishing a campus-wide pain research program (see the “Report of the Pain and Neurosensory Research Think Tank”). The workshop culminated in development of a plan for building a world-class, comprehensive pain research program on the NIH campus with NIDCR and NINDS serving as leads and participation from several other institutes. NIDCR and NINDS are currently engaged in discussions aimed at finding common ground for creation of this program. (ii) Under the leadership of Dr. Silvio Gutkind, the NIDCR is exploring with NCI and NIDCD the possibility of building a joint bench-to-bedside program or initiative in head and neck cancer research. This planned initiative has allowed us to partner with the Cancer Genome Anatomy Project (CGAP), and to work toward a joint clinical research program in head and neck cancer. (iii) The NIDCR is continuing efforts to explore and partner with other ICs to build a state-of-the-art skeletal diseases research program. Dr. Pamela Gehron Robey continues to play an important leadership role in these efforts.

### **NIDCR Clinical Research**

During the past year, the Division’s clinical research activities grew significantly. Presently all seven Branches are engaged in clinical research, albeit to different degrees and at different stages of development. As an example, the Craniofacial and Skeletal Diseases Branch (CSDB) developed its three first protocols last year. This research will enable Branch scientists to rapidly move their basic research findings in skeletal biology to the clinic.

The Pain and Neurosensory Mechanisms Branch (PNMB) was reviewed by the Board of Scientific Counselors in June of 1998. The Branch received many positive and encouraging comments for the significance and uniqueness of its research, as well as some constructive critique for enhancing its program. In order to meet a need often expressed by the members of the Board, the December meeting was dedicated to providing a comprehensive overview of the DIR’s research activities. Each Branch and single standing Unit presented and discussed its research at a meeting convened on December 3, 1998. The BSC also conducted a highly successful tenure track mid-term review of Dr. Ashok Kulkarni. We were pleased that three members of the National Advisory Dental Research Council, NADRC, (Dr. Harold Morris,



Dr. Caswell Evans, Dr. Michael Rethman) were also able to join us and learn more about our scientific programs.

## **Scientific Collaborations**

During the past year NIDCR scientists enjoyed extensive interactions with the extramural community by presenting their research findings at scientific meetings, universities and private industry. Many also served as advisors to industry, government and academia and contributed to the advancement of science through participation in professional and scientific organizations, including editorial board memberships and editorships, etc. All of these activities are detailed in the document "Interactions with Scientific Community." Moreover, the Division hosted over 50 outstanding scientists from the US and abroad to NIH as seminar speakers and consultants.

## **Training**

Pursuant to the Institute's commitment to creating a learning environment as outlined in the NIDCR Strategic Plan, the Division established an Office of Education. The Office coordinates and administers all divisional programs that relate to training and education and serves as a liaison to any and all related Institute- and NIH-wide activities, agencies and programs. The Office also serves as a conduit to all national and international activities that relate to training issues. Following a national search, Dr. Sharon Gordon was selected as Director of the Office of Education.

FY98 was a very active and, in many respects, innovative year for NIDCR student research programs. It marked the third successful year of the nationally competitive "NIDCR Summer Dental Student Award." In addition, the Division hosted a Howard Hughes Fellow (Mr. Mark Berkman, Ohio State University), and a participant in the Clinical Center Clinical Research Program (Mr. Clifford Davis, UCLA). To further expand these opportunities, the Division established a new, one-year research program for dental students based on the Howard Hughes experience (Mr. Michael Palante, New Jersey). The Division was also successful in attracting three Hispanic students for short-term training under the provision of the Hispanic Association of Colleges and Universities program. In order to help expand efforts to recruit young underrepresented minority scientists, this year the Division took an important first step toward establishing personal connections and liaisons with predominantly Hispanic institutions and with Native American institutions. In 1998 teams representing the Division and the Office of the Director visited three institutions in New Mexico and Puerto Rico to introduce young, future scientists to the potential opportunities available in the NIDCR.

In another initiative to more effectively recruit young scientists among traditionally underrepresented minorities, the Division established an incentive program that provides partial support for two years from the Office of the Scientific Director to Senior Investigators who recruit Hispanic, African-American or Native American fellows. The program has already been successful in helping expand DIR outreach programs for fellows and students.

## **Planning Activities, Retreats and Workshops**

To more specifically review and assess future clinical research opportunities in the NIH environment, the DIR convened a group of outside experts from NIH and from the extramural community on May 18-19, 1998. A subgroup of this panel also reviewed and critiqued recent progress made on DIR clinical protocols. This one-day workshop produced many constructive and thoughtful ideas that are likely to further strengthen and energize the NIDCR clinical research agenda. (Details of the recommendations may be found in the “Clinical Research Opportunities Workshop Summary”).

The Division leadership and the Senior Investigators participated in a two-day retreat at Harbortowne Conference Center, St. Michaels, Maryland, September 24-25, 1998. The meeting provided a valuable opportunity to assess recent DIR organizational changes, to evaluate progress toward implementation of the NIDCR Strategic Plan, and to identify overall program priorities for the future. Additional details of the immediate and future program priorities may be found in the “DIR Five Year Plan.”

## **Renovation Program in Building 30 and Building 10**

During the past year the Division embarked on a much needed and long overdue renovation program in Building 30 and in Building 10. Many of our laboratories are out-moded and incommensurate with the state-of-the-art research being conducted in the DIR. The Division plans to allocate a significant portion of its future budget growth to the renovation process.

## **Scientific Highlights and Accomplishments**

While the administrative and organizational changes of the past year required a significant amount of effort and energy from our staff, I am very pleased that our investigators remained highly productive and widely shared their research findings in publications; in presentations at meetings and seminars; and in talks at institutions across the country. These many scientific accomplishments are detailed by Branch in a separate document and the highlights are summarized in the Division Summary immediately following this introduction.

Other activities of the year, and important background information, may be found in these DIR or NIDCR documents:

*“Shaping the Future. The NIDCR Strategic Plan”*

*DIR Reorganization Plan: “The Division of Intramural Research, November 15, 1996”*

*Clinical Research Opportunities Workshop Summary*

*Report of the Pain and Neurosensory Research Think Tank*

*The DIR Five Year Plan: “Scientific Opportunities for Growth and Expansion”*

*Article in JADA by H. Birkedal-Hansen*

*DIR “Interactions with Scientific Community”*

CRANIOFACIAL  
DEVELOPMENTAL BIOLOGY  
AND  
REGENERATION  
BRANCH

*Kenneth Yamada*  
*Hynda Kleinman*  
*Yoshihiko Yamada*





## CRANIOFACIAL DEVELOPMENTAL BIOLOGY AND REGENERATION BRANCH 1998

Our Branch continues to generate a variety of exciting research advances and to receive international recognition. We also continue to place a high priority on the training of young scientists to become independent leaders in academia and industry. In addition, we provide extensive service and citizenship activities on behalf of NIDCR, NIH, and our research fields. Our Branch mission spans the range from basic research through clinical. Our goals focus on creating research breakthroughs (a) to understand the mechanisms of normal and abnormal craniofacial development and function at the genetic, molecular, and cell biological levels, (b) to discover and refine new biologicals and biomimetics relevant to diagnosis, repair, and therapy, and (c) to develop creative, biologically based methods to regenerate craniofacial tissues that are defective or damaged. Our Branch continues to explore important fundamental questions in development, regeneration, and related fields, including the molecular and cell biological mechanisms of morphogenesis, structure and function of extracellular matrix and its receptors, tissue organization, signaling from the cell surface to the nucleus for novel gene induction, cellular differentiation, and the mechanisms of cancer cell growth and metastasis. Discoveries and ongoing innovations in basic research will provide the basis for novel translational and patient-oriented applications.

Members of CDBRB were again invited this year as featured speakers at a variety of international meetings and symposia. Examples of meeting presentations from this past fiscal year included H. Kleinman at a conference on "Cellular, Molecular and Genetic Aspects of Aging" in Israel and K. Yamada as a Plenary Lecturer at the Third Congress of the Asian Pacific Organization for Cell Biology in Japan.

Members of the Branch also continue to serve on the editorial boards of a number of leading journals including J. Cell Biology (H. Kleinman on the board, and K. Yamada as an Associate Editor), J. Biological Chemistry (H. Kleinman), J. Cellular Physiology (K. Yamada, Editor), J. Cell Science (K. Yamada), and Cancer Research (H. Kleinman). H. Kleinman also serves on five other journal boards including J. National Cancer Institute and Angiogenesis, and K. Yamada serves on seven other boards including Current Protocols in Cell Biology and J. Craniofacial Genetics and Developmental Biology. Members also serve on NIH and U.S. Army study sections (H. Kleinman) and on the Council of the International Society for Matrix Biology (K. Yamada). Members of our Branch also provide extensive service on more than 30 NIH and NIDCR committees, including the NIH Biomedical Research Service Policy Board, NIH Diversity Council, NIH Scientific Conduct and Ethics Committee, Search Committee for Director of the NIDCR Division of Extramural Research, and NIDCR Tenure and Promotion Committee.

Our Branch distributes its research products extensively by licensing materials, donating them to repositories, and providing numerous gifts to research colleagues. Products generated by members of the Laboratory that are currently being licensed by companies include Matrigel and invasion substrates (Collaborative/Becton Dickinson and Sigma) and monoclonal antibodies against integrins (Becton Dickinson). The Branch has donated the EHS sarcoma to ATCC along with approximately 500 cDNA clones. We will have dozens of new, formal Material Transfer

Agreements with non-NIDCR researchers this year. Members of the Branch have also received support from outside organizations. Significant support for research on proteoglycans was received from Seikagaku. NASA provided funds to study salivary gland cell differentiation in microgravity. Non-NIH salary support for postdoctoral members of the Laboratory has come a wide variety of sources including the Japan Society for the Promotion of Science, the Dutch Cancer Society, the French CNRS, the German government, the Japanese Ministry of Education, and the Spanish government. The Branch also has a Cooperative Research and Development Agreement (CRADA) with the biotechnology company Trevigen, focusing on novel molecular approaches to wound repair.

Researchers in the Craniofacial Developmental Biology and Regeneration Branch have made substantial research progress and exciting scientific breakthroughs during the past year, and our annual report bibliography lists over 80 publications. A variety of arbitrarily selected research advances are highlighted below. The project reports from each Section provide more comprehensive summaries of the major new findings in our Branch.

New research initiatives in all three sections are identifying and characterizing proteins and genes important for tooth and craniofacial development and cancer. Hundreds of novel genes (i.e., genes never previously described) have been identified by partial sequencing of rodent tooth and embryonic craniofacial unidirectional cDNA libraries, as well as of human salivary gland subtraction libraries. Selected novel genes show interesting and quite distinctive mRNA expression patterns in developing tissues; several genes are expressed preferentially in early mouse embryos. A contract is currently underway to generate antibodies against murine gene products of interest. Branch members are also the contract officers of a major new contract to be awarded shortly to discover and catalogue expression patterns of human craniofacial genes that are active during early development. All clones and antibodies will continue to be made freely available to dental scientists and to other qualified investigators to promote research in the area. The first protein to be characterized by the CDBRB using these approaches was ameloblastin, discovered to be a novel tooth-specific, developmentally regulated gene product associated with enamel formation and linked to the congenital disorder amelogenesis imperfecta. Other genes can be used similarly as candidates for the identification of genetically linked diseases and disorders of oral and craniofacial tissues.

New transcription factors and mechanisms of gene regulation essential for normal development are being characterized, such as a novel Kruppel zinc finger protein found to be essential for normal tooth development. The Molecular Biology Section has also characterized the enhancer of the link protein gene and protein factors that selectively inhibit enhancer activity of two types of cartilage-specific collagen genes. This Section has also identified a 6 bp sequence in intron 1 of the  $\alpha 2(XI)$  collagen gene critical for cartilage-specific transcription of the gene. The Developmental Mechanisms Section has characterized craniofacial and other sites of expression of the zinc finger protein termed Slug, shown to be essential for an initial step in the morphogenetic process of epithelial-to-mesenchymal transformation. Our knowledge about new genes and regulatory mechanisms is being used to examine pathology in animal models and in human diseases. For example, the Molecular Biology Section has created gene knockout mice to study the biological roles of link protein and perlecan.



Laminin and laminin peptides have been implicated by Branch members in angiogenesis, neurite outgrowth, and tumor growth and metastasis. Over 700 overlapping laminin peptides spanning the entire laminin molecule are being tested in a variety of biological processes by the Molecular and Cell Biology Sections. Over 40 of these peptides have cell-type specific effects on cell adhesion, growth, angiogenesis, or salivary gland differentiation; several are highly potent. Another peptide can switch on the metastatic phenotype to help study this process. Comparisons of the functions, cell-type specificity, receptors, and signaling mechanisms of these peptides are in progress. These studies should lead to the development of new therapeutic reagents.

The interaction of cells with extracellular matrix via integrin receptors induces altered signaling, cytoskeletal organization, gene expression, growth, and differentiation. The newly described tumor suppressor termed PTEN/MMAC1, which is mutated in 10-45% of various types of human tumors, was discovered by the Developmental Mechanisms Section to be a potent down-regulator of integrin-mediated functions, including cell migration and spreading. It specifically dephosphorylates key proteins such as focal adhesion kinase and p130<sup>Cas</sup>. It also appears to target MAP kinase signaling, which is a crucial cellular regulator of growth and differentiation. New technologies are being developed by this Section to study these signaling processes. One approach has adapted synthetic leucine zipper domains for the formation of specific inter-molecular hybrids to provide a method to the localization of any protein in a cell. Another is the use of molecular chimeras to examine the roles of transmembrane clustering of cytoplasmic molecules in signal transduction.

Novel extracellular regulators of cell migration and tumor metastasis have been identified by the Cell Biology Section. Ongoing studies on thymosin  $\beta$ 4 and thymosin  $\alpha$ 1 have established roles in endothelial cell migration, and acceleration of wound repair in a rat skin biopsy model, suggesting a potential application in promoting human wound healing. A novel function for osteonectin was also identified in supporting prostate cancer cell metastasis to bone and induction of proteases. Several patent applications were filed for potential clinical use of thymosin  $\alpha$ 1, thymosin  $\beta$ 4, and osteonectin.

The specific molecules and stages of cellular responses to matrix are being characterized in human salivary gland (HSG) cells and in fibroblasts by the Cell Biology and Developmental Mechanisms Sections. When salivary gland cells are placed on extracellular matrix proteins in cell culture, they show large changes in gene expression and protein biosynthesis. More than two dozen genes were identified as induced by integrin-mediated adhesion of salivary cells to collagen or fibronectin, many of them completely novel. On a basement membrane extract, salivary gland cells can differentiate and form mini-glands. This process of differentiation involves an 8-amino acid sequence in laminin whose cellular receptor has been found to be syndecan-1. Growth factors needed for differentiation are also being characterized, and other genes induced after adhesion to basement membrane substrates are being sought. These studies in cell culture systems are building the knowledge base necessary to develop creative therapeutic approaches for the repair or replacement of salivary glands and other tissues. For example, CDBRB is collaborating with the Gene Therapy and Therapeutics Branch toward the ambitious goal of developing an artificial salivary gland, and a joint invention report was filed describing



this concept. These and other exciting advances are described in the following list of publications and in reports on specific projects from each Section.

## **CRANIOFACIAL DEVELOPMENTAL BIOLOGY AND REGENERATION BRANCH 1998 BIBLIOGRAPHY**

Aota S, Yamada KM. Integrin functions and signal transduction. *Adv Exp Med Biol* 1997; 400B:669-82.

Ariel A, HersHKoviz R, Cahalon L, Williams DE, Akiyama SK, Yamada KM, Chen C, Alon R, Lapidor T, Lider O. Induction of T cell adhesion to extracellular matrix or endothelial cell ligands by soluble or matrix-bound interleukin-7. *Eur J Immunol* 1997;27:2562-70.

Baum BJ, Wang S, Cukierman E, Delporte C, Kagami H, Marmary Y, Fox PC, Mooney DJ, Yamada KM. Re-engineering the functions of a terminally-differentiated epithelial cell line in vivo. *Ann NY Acad Sci* 1998, in press.

Brown JC, Sasaki T, Göhring W, Yamada Y, Timpl R. Carboxyterminal domain V of perlecan promotes  $\beta 1$  integrin-mediated cell adhesion, binds heparin, nidogen, and fibulin-2 and can be modified by glycosaminoglycans. *Eur J Biochem* 1997;250:39-46.

Cid MC, Hernandez-Rodriguez J, Robert J, del Rio A, Casademont J, Grau JM, Kleinman HK, Urbano-Marquez A, Cardellach R. Interferon- $\alpha$  may exacerbate cryoglobulinemia-derived ischemic manifestations. An adverse effect potentially related to its anti-angiogenic activity. *Arth Rheum* 1998, in press.

Copie V, Tomita Y, Akiyama SK, Aota S, Yamada KM, Venable RM, Pastor RW, Krueger S, Torchia DA. Solution structure and dynamics of linked cell attachment modules of mouse fibronectin containing the RGD and synergy regions: comparison with the human fibronectin crystal structure. *J Mol Biol* 1998;277:663-82.

Danen EHJ, Lafrenie RM, Miyamoto S, Yamada KM. Integrin signaling: Cytoskeletal complexes, MAP kinase activation, and regulation of gene expression. *Cell Adhesion Commun* 1998, in press.

De Nichilo MO, Katz B-Z, O'Connell B, Yamada KM. De novo expression of pp125<sup>FAK</sup> in human macrophages regulates CSK distribution and MAP kinase activation but does not affect focal contact structure. *J Cell Physiol* 1998, in press.

Fleischmajer J, Kühn K, Sato Y, MacDonald DE II, Perish J S, Pan T-E, Chu L-E, Kishiro Y, Oonishi T, Bernier S, Yamada Y, Ninomiya Y. There is temporal and spatial expression of  $\alpha 1(IV)$ ,  $\alpha 2(IV)$ ,  $\alpha 5(IV)$ ,  $\alpha 6(IV)$  collagen chains and  $\beta 1$  integrin during development of the basal lamina in an *in vitro* skin model. *J Invest Dermatol* 1997;109:527-33.

Fleischmajer J, Utani A, MacDonald DE II, Perish JS, Schechter A, Pan T-E, Chu L-E, Ninomiya Y, Yamada Y. Initiation of skin basement membrane formation at the epidermo-dermal interface involves assembly of laminin-1 and laminin-5 through binding to cell membrane receptors. *J Cell Sci* 1998, in press.

Fukae M, Tanabe T, Uchida T, Lee SK, Tryu OK, Murakami C, Wakida, K, Simmer JP, Yamada Y, Bartlett JD. Enamelysin (matrix metalloproteinase-20) localization in the developing tooth and effects of pH and calcium on amelogenin hydrolysis. *J Dent Res* 1998, in press.

Fukuda K, Hori H, Utani A, Burbelo PD, Yamada Y. Formation of recombinant triple-helical [ $\alpha$ 1(IV)] $_2$  $\alpha$ 2(IV) collagen molecules in CHO cells. *Biochem Biophys Res Comm* 1997;231:178-82.

Haralabopoulos GC, Grant DS, Kleinman HK, Maragoudakis ME. Thrombin promotes endothelial cells alignment on matrigel in vitro and angiogenesis in vivo. *Am J Physiol* 1997;273:C239-C245.

Hoffman MP. Pathways to organogenesis: from coconut crazed teeth in Tonga to salivary glands in space. *New Zealand Dent J* 1998;94:117-18.

Hoffman MP, Nomizu M, Roque E, Lee SK, Jung D, Yamada Y, Kleinman HK. Laminin-1 and laminin-2 G-domain synthetic peptides bind syndecan-1 and are involved in acinar formation of a human submandibular gland (HSG) cell line. *J Biol Chem* 1998, in press.

Kadoya Y, Nomizu M, Sorokin LM, Yamashina S, Yamada Y. Laminin  $\alpha$ 1 chain G domain peptide, RKRLQVQLSIRT, inhibits epithelial branching morphogenesis of cultured embryonic mouse submandibular gland. *Dev Dynamics* 1998, in press.

Katz B-Z, Krylov D, Aota S, Olive M, Vinson C, Yamada KM. Green fluorescent protein labeling of cytoskeletal structures -- A novel targeting approach based on leucine zippers. *Biotechniques* 1998;25:298-304.

Katz B-Z, Levenberg S, Yamada KM, Geiger B. Modulation of cell-cell adherens junctions by surface clustering of the N-cadherin cytoplasmic tail. *Exp Cell Res* 1998, in press.

Katz B-Z, Yamada KM. Integrins in morphogenesis and signaling. *Biochimie* 1997; 79: 467-76.

Kim WH, Jun SH, Song SY, Kleinman HK. Expression of the 32/67KD laminin receptor in laminin-adhesion-selected human colon cancer cell lines. *Br J Cancer* 1997;77:15-20.

Kim WH, Nomizu M, Song S-Y, Tanaka K, Kuratomi Y, Kleinman HK, Yamada Y. Identification of a laminin alpha 1 chain sequence leu-gln-val-glu-leu-ser-ile-arg (LQVQLSIR) active in melanoma cell metastasis to the liver. *Int J Cancer* 1998;77:632-9.

Kleinman HK. Preparation of basement membrane components from the EHS tumor: Matrigel, laminin and collagen IV and preparation of gelled substrates, matrigel and collagen I, for culture and in vivo studies. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM, eds. *Current Protocols in Cell Biology*. New York, NY: John Wiley and Sons 1998, in press.

Kleinman HK, Cid MC. Preparation of endothelial cells. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM, eds. *Current Protocols in Cell Biology*. New York, NY: John Wiley and Sons, Inc., 1998, in press.

Kleinman HK, Grant DS, Malinda KM. Role of thymic peptides in wound healing. In: Fan T-P, Auerbach R, eds. *The New Angiotherapy*. New Jersey: Humana Press, 1998, in press.

Kleinman HK, Jacob K. Invasion assays. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM. Eds. *Current Protocols in Cell Biology*. New York, NY: John Wiley and Sons 1998, in press.

Kleinman HK, Malinda KM. Role of angiogenesis in wound healing. In: Mousa S, D'Amato R, eds. *Therapeutic Implication of Angiogenesis Inhibitors and Stimulators: Current Status and Future Directions*. Texas: Landes Bioscience, 1998, in press.

Kleinman HK, Malinda KM, Ponce ML. Extracellular matrix. In: Bikfalvi A, ed. *Comprehensive Vascular Biology and Pathology-An Encyclopedic Reference*. Heidelberg, Germany: Springer Verlag 1998, in press.

Kleinman HK, Weeks BS, Johnson B, Kibbey MC. Laminin in neuronal development. *Encyclopedia of Human Biology*: 2<sup>nd</sup> Edition. New York, NY: Academic Press 1997;5:227-35.

Komatsu T, Kanatsu K, Kuze K, Iehara N, Takeoka H, Yamada Y, Kita T, Doi T. Demonstration of DNA replication factor C in human glomerular lesion. *Clin Nephrology* 1998;49:69-73.

Kuze K, Sunamoto M, Komatsu T, Iehara N, Takeoka H, Yamada Y, Kita T, Doi T. A novel transcription factor is correlated with both glomerular proliferation and sclerosis in the rat renal ablation model. *J Pathol* 1997;183:16-73.

Lafrenie RM, Bernier SM, Yamada KM. Adhesion to fibronectin or collagen I gel induces rapid, extensive biosynthetic alterations in epithelial cells. *J Cell Physiol* 1998;175:163-73.

Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. *J Immunol* 1997;159:4077-83.

Lafrenie RM, Yamada KM. Integrins and matrix molecules in salivary gland cell adhesion, signaling, and gene expression. *Ann NY Acad Sci* 1998;842:42-8.



Lee S-K, Malpeli M, Cancedda R, Utani A, Yamada Y, Kleinman HK. Laminin chain expression by chick chondrocytes and mouse cartilaginous tissues in vivo and in vitro. *Exp Cell Res* 1997;236:212-22.

Lentini A, Kleinman HK, Mattioli P, Nicolini L, Cardinali M, Beninati S. Inhibition of experimental metastasis by methylxanthines in mice: Impairment of two distinct stages of B16-F10 lung invasion. *Melanoma Res* 1998;8:131-7.

Levenberg S, Katz B-Z, Yamada KM, Geiger B. Long-range and selective autoregulation of cell-cell or cell-matrix adhesions by cadherin or integrin ligands. *J Cell Sci* 1997;111:347-57.

Lietard J, Musso O, Theret N, L'Héroguez A, Campion JP, Yamada Y, Clement B. Sp1-mediated transactivation of LamC1 promoter and coordinated expression of laminin- $\gamma$ 1 and Sp1 in human hepatocellular carcinomas. *Am J Pathol* 1997;151:1663-72.

Lim SD, Bae SI, Kim IG, Park SC, Chung SI, Nomizu M, Kleinman HK, Kim WH. Tissue transglutaminase is not increased during apoptosis of HT-1080 human fibrosarcoma cells. *Exp Tox Path* 1998;50:79-82.

Liu Y, Watanabe H, Nifuji A, Yamada Y, Olson EN, Noda M. Overexpression of a single helix-loop-helix transcription factor, scleraxis, enhances aggrecan gene expression in osteoblastic osteosarcoma ROS17/2.8 cells. *J Biol Chem* 1997;271:29880-5.

Malinda KM, Nomizu M, Chung M, Delgado M, Yamada Y, Kleinman HK, Ponce ML. Identification of laminin  $\alpha$ 1 and  $\beta$ 1 chain peptides active for endothelial cell adhesion, tube formation and aortic sprouting. *FASEB J* 1998, in press.

Malinda KM, Sidhu GS, Banaudha KK, Gaddipati JP, Maheshwari RK, Goldstein A, Kleinman HK. Thymosin  $\alpha$ 1 stimulates endothelial cell migration and wound healing. *J Immunol* 1998;160:1001-6.

Michigami T, Nomizu M, Yamada Y, Dunstan C, Williams PJ, Mundy GR, Yoneda T. Role of laminin in tumorigenicity and metastatic potential of a murine B-cell lymphoma in an animal model of spontaneous metastasis: Inhibitory effects of multimeric form of laminin peptide YIGSR. *Clin Exp Metastasis* 1998, in press.

Miyamoto S, Katz B-Z, Lafrenie RM, Yamada KM. Fibronectin and integrins in cell adhesion, signaling, and morphogenesis. *Ann NY Acad Sci* 1998, in press.

Montesano R, Soriano JV, Malinda KM, Ponce ML, Kleinman HK, Bonifacino A, Bottaro DP, Aaronson, SA. Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial cell tubulogenesis. *Cell Growth Differ* 1998;9:355-65.

Nakahara H, Muller SC, Yamada Y, Chen W-T. Activation of  $\beta 1$  integrin signaling of cell invasion stimulates tyrosine phosphorylation and complex formation of p190rhoGAP. *J Biol Chem* 1998;273:9-12.

Nanci A, Zalzal S, Lavoie P, Kunikata M, Chen W-Y, Krebsbach PH, Yamada Y, Hammarstrom L, Simmer JP, Finchman AG, Snead ML, Smith CE. Comparative immunochemical analyses of the developmental expression and distribution of ameloblastin and amelogenin in rat incisors. *J Histochem Cytochem* 1998, in press.

Nomizu M, Kuratomi Y, Malinda KM, Song SY, Miyoshi K, Otaka A, Powell SK, Hoffman MP, Kleinman HK, Yamada Y. Cell binding sequences of mouse laminin  $\alpha 1$  chain. *J Biol Chem* 1998, in press.

Nomizu M, Kuratomi Y, Song SY, Ponce LM, Hoffman MP, Powell SK, Miyoshi K, Otaka A, Kleinman HK, Yamada Y. Identification of cell binding sequences in mouse laminin  $\gamma 1$  chain by systematic peptide screening. *J Biol Chem* 1997;272:32198-205.

Paine ML, Krebsbach PH, Chen LS, Paine CT, Yamada Y, Deutsch D, Snead ML. Protein to protein interactions: criteria defining the assembly of the enamel organic matrix. *J Dent Res* 1998;77:496-502.

Ponce ML, Cid MC, Kim-Schulze S, Malinda KM, Grant DS, Schnaper HW, Kleinman HK. Role of estrogen in endothelial cell behavior. In: Rubanyi G, Kauffman R, eds. *Estrogen and the Vessel Wall*. Chur, Switzerland: Harwood Academic Publisher, 1998;63-72.

Powell SK, Williams CC, Nomizu M, Yamada Y, Kleinman HK. Laminin-1 and laminin-2 are differentially regulated during cerebellar development and stimulate granule cell neurite outgrowth in vitro. *J Neuroscience Res* 1998, in press.

Savagner P, Karavanova I, Perantoni A, Thiery JP, Yamada KM. Slug mRNA is expressed by specific mesodermal derivatives during rodent organogenesis. *Devel Dynamics* 1998, in press.

Simmons D, Gu T, Krebsbach PH, Yamada Y, MacDougall M. Identification and characterization of cDNA for murine ameloblastin. *J Bone Miner Res* 1998, in press.

Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho M-P, Yamada KM, Zardi L, Murphy G. The activation of proMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. *J Cell Sci* 1998, in press.

Song SY, Kleinman HK. In vitro invasion through Matrigel. In: Mikkelsen T, Bjerkvig R, Laerum O, Rosenblum ML, eds. *Brain Tumor Invasion*. New York, NY: John Wiley and Sons 1998;203-17.

- Song S-Y, Nomizu M, Yamada Y, Kleinman HK. Liver metastasis formation by laminin-1 peptide (LQVQLSIR)-adhesion selected B16-F10 melanoma cells. *Int J Cancer* 1997;71:436-41.
- Takami H, Utani A, Kozak C, Yamada Y, Burbelo P. Cloning, sequence analysis and chromosomal assignment of the mouse gene for p190-B. *Biochem Biophys Acta* 1998, in press.
- Takcoka H, Iehara N, Uematsu-Yanagita M, Abe H, Sunamoto M, Yamada Y, Doi T. A multifunctional transcription factor (A1P145) regulates the smooth muscle phenotype in mesangial cells. *Biochem Biophys Res Comm* 1998, in press.
- Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. *Science* 1998;280:1614-17.
- Talts JF, Mann K, Yamada Y, Timpl R. Structural analysis and proteolytic processing of recombinant G domain of mouse laminin  $\alpha 2$  chain. *FEBS Lett* 1998;426:71-6.
- Thaloor D, Singh AK, Sidhu GS, Paruchuri VP, Kleinman HK, Maheshwari RK. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. *Cell Growth Differ* 1998;9:305-12.
- Tsumaki N, Kimura A, Tanaka K, Kimura JH, Ochi T, Yamada Y. Molecular arrangement of cartilage- and neural tissue-specific cis-elements in the mouse  $\alpha 2(XI)$  collagen promoter. *J Biol Chem* 1998, in press.
- Tsumaki N, Liu Y, Yamada Y, Krebsbach P. Enhancer analysis of the  $\alpha 1(II)$  and  $\alpha 2(XI)$  collagen genes in transfected chondrocytes and transgenic mice. In: Streuli C, Grant M, eds. *Methods in Molecular Biology: Extracellular Matrix*. Totowa, NJ: Humana Press 1998, in press.
- Utani A, Nomizu M, Yamada Y. Fibulin-2 binds to the short arms of laminin-5 and laminin-1 via conserved amino acid sequences. *J Biol Chem* 1997;272:2814-20.
- Wahl LM, Kleinman HK. Tumor associated macrophages as targets for cancer therapy. *J Natl Cancer Inst* 1998, in press.
- Wai AWK, Ng LJ, Watanabe H, Yamada Y, Tam PPL, Cheah KSE. Disrupted expression of matrix genes in the growth plate of the mouse cartilage matrix deficiency (cmd) mutant. *Dev Genetics* 1998, in press.
- Watanabe H, Cheung SC, Itano N, Kimata K, Yamada Y. Identification of hyaluronan-binding domain of aggrecan. *J Biol Chem* 1997;272: 28057-65.
- Watanabe H, Yamada Y. Aggrecan: structure and role in genetic disorders in extracellular matrix-cellular interaction. In: Ninomiya Y, Olsen B, eds. *Extracellular Matrix-Cellular Interaction: Molecules to Diseases*. Tokyo, Japan: S Karger Basel 1998, in press.



Weeks BS, Nomizu M, Ramchandran RS, Yamada Y, Kleinman HK. Laminin-1 and RKRLQVQLSIR laminin alpha 1 chain peptide stimulate matrix metalloproteinase secretion by PC12 cells. *Exp Cell Res* 1998, in press.

Yamada KM. Book Review: Cytoskeletal-Membrane Interactions and Signal Transduction. In: Cowin P, Klymkowsky MW. *Mol Membrane Biol* 1998, in press.

Yamada, KM. Cell Adhesion Molecules. In: *Encyclopedia of Molecular Biology*, Creighton TE, ed. New York: John Wiley & sons, 1998, in press.

Yamada KM. Introduction to Chapter 9: Cell Adhesion. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM, eds. *Current Protocols in Cell Biology*. New York: John Wiley & Sons, 1998, in press.

Yamada KM. Introduction to Chapter 10: Extracellular Matrix. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM, eds. *Current Protocols in Cell Biology*. New York: John Wiley & Sons, 1998, in press.

Yamada KM. Introduction to Chapter 14: Signal Transduction: Protein Phosphorylation. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM, eds. *Current Protocols in Cell Biology*. New York: John Wiley & Sons, 1998, in press.

Yamada KM, Danen EHJ. Integrin signaling. In: Gutkind S, ed. *Signal Transduction, Cell Cycle, and Their Inhibitors*. New Jersey: Humana Press, 1998, in press.

Yamazaki Y, Savva M, Kleinman HK, Oka S, Mokotoff M. Enhanced cleavage of diaminopimelate-containing isopeptides by leucine aminopeptidase and matrix metalloproteinases in tumors. Applications to bioadhesive peptides. *J Peptide Res* 1998, in press.

Yin Z, Giacomello E, Gabriele E, Zardi L, Aota S, Yamada KM, Skerlavaji B, Doliana R, Colombatti A, Perris R. Cooperative activity of  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  integrins in mediating human B cell lymphoma adhesion and chemotaxis on fibronectin through recognition of multiple synergizing binding sites within the central cell-binding domain. *Blood* 1998, in press.

Yurchenco PD, Quan Y, Colognato H, Mathus T, Harrison D, Yamada Y, O'Rear JJ. The  $\alpha$  chain of laminin-1 is independently secreted and drives secretion of its  $\beta$  and  $\gamma$  chain partners. *Proc Natl Acad Sci USA* 1997;94:10189-94.

Zheng C, Hoffman MP, McMillan T, Kleinman HK, O'Connell BC. Growth factor regulation of the amylase promoter in differentiating salivary gland acinar cells. *J Cell Physiol* 1998, in press.

Zohar M, Teramoto H, Katz B-Z, Yamada KM, Gutkind JS. Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation. *Oncogene* 1998, in press.



Zukowska-Grojec Z, Darwatowska-Rrokopezuk E, Rose W, Rone J, Simon J, Yeh YY, Chen WT, Kleinman HK, Grant DS. Neuropeptide Y (NPY) from the sympathetic nerves is angiogenic. *Circulation Res* 1998;83:187-95.



# CRANIOFACIAL AND SKELETAL DISEASES BRANCH

*Pamela Gehron Robey*

*Edward David Eanes*

*Larry W. Fisher*

*Marian F. Young*



## CRANIOFACIAL AND SKELETAL DISEASES BRANCH 1998

During the past fiscal year, the Branch has continued to focus its efforts on determining the processes by which skeletal elements are modeled during embryogenesis, remodeled and maintained in the post-natal organism, and how these processes are altered in disease states that affect the skeleton. This focus is fostered through the coordinated efforts of senior investigators working in the areas of developmental biology, cell and molecular biology, and protein and mineral chemistry. Furthermore, the translation of these efforts into clinical studies and applications has been, and remains a major area of emphasis in the Branch. A national search for a chief of this Skeletal Clinical Studies demonstrates the commitment of the Branch to the latter area. Two highly qualified candidates were identified, however, the position remains unfilled. Nonetheless, efforts in translational and clinical research are progressing rapidly through the addition of clinically trained junior staff, a continuation of the Georgetown University Orthopaedic Residents Training Program, establishment of collaborations with other NIH Institutes, institutions around the world, and the use of outside consultants. In addition, the Branch has joined forces with members of the Molecular Genetics Branch of NHGRI to establish the Skeletal Genome Anatomy Project (SGAP) which is designed to aid in gene discovery and to determine changes in the pattern of gene expression of skeletally derived cells as a function of developmental age and of disease processes. The Branch has made major advances in several areas, as is highlighted below, which represents not only progress within each Senior Investigator (SI) group, but a great deal of interaction between SI groups and collaborators at NIH and around the world.

### Developmental Biology

This program focuses on the signaling molecules involved in skeletal development and joint morphogenesis. Although the primary investigator of the group, Dr. Frank Luyten, left the NIDR in the fall of 1997, Dr. John Terrig Thomas, a Visiting Associate, has remained to complete several ongoing projects. Previously, the group had isolated two new members of the TGF-beta superfamily, CDMP-1 and CDMP-2, which are expressed in the cartilage condensations and in the interzone region of future joint spaces during limb development. From the study of three different inherited chondrodysplasias, it was demonstrated that CDMP-1 plays a critical role in the development of the appendicular skeleton. Having isolated both mouse and human *cdmp-1*, transient transgenic experiments are underway to determine the location of the cartilage and joint-specific regulatory elements in CDMP-1. Another protein, Frzb (pronounced "frisbee") was initially isolated from purified cartilage extracts and shares homology to the cysteine rich domain (CRD) of *frizzled*, a Wnt receptor. Wnt proteins are secreted signaling molecules having numerous developmental functions, including skeletal development, as well as dysfunction in oncogenesis. Frzb is able to bind to and inactivate Wnt activity leading to speculation for a potential therapeutic in modifying Wnt induced developmental and oncogenic events. It has been shown that Frzb is temporally and spatially expressed during skeletal and craniofacial development and the present aim is to determine the exact function of Frzb during skeletogenesis using the Cre-LoxP recombination system, whereby the effect of loss of Frzb function at various stages of development can be observed. Chimeric "floxed" mice have been obtained and

germline transmission is currently being confirmed. The generation of “floxed”-*frzb* mice will provide a powerful tool to study the role of Frzb, and thus indirectly, Wnt signaling, in any organ system in which Frzb displays an interesting expression pattern either during development or postnatally. In addition, the regulatory elements of *frzb* are being identified which will provide useful information as to the control of its temporal and spatial expression pattern.

## **Skeletal Biology**

The Skeletal Biology program, headed by Dr. Pamela Gehron Robey, has focused on biochemically characterizing osteogenic cells, including bone marrow stromal cells (BMSCs), a heterogeneous population of clonogenic cells that give rise to osteoblasts/chondrocytes, adipocytes and hematopoiesis supportive stroma. Studies were designed to test the hypothesis that different members of the stromal cell population represent pluripotential cells, while others are more committed to particular phenotypes. This hypothesis was tested by determining the ability of individual clones of human BMSCs to form a bone/bone marrow organ by using a newly developed in vivo transplantation system. It was found that 54% of the clones studied supported bone formation, but only half of these clones supported bone formation and hematopoiesis. These results prove that some, but not all, of the members of the stromal cell population maintain their ability to form bone, hematopoiesis supportive stroma and associated adipocytes. The differences between non-bone forming clones, clones that form bone were further investigated by examining their expression of receptor tyrosine kinases (RTKs), a family of receptors that has been implicated in the proliferation and differentiation of many connective tissue cells. PDGF-receptor beta, EGF receptor, FGF receptor-1 and Axl were identified in the multi-colony derived population of BMSCs. Clonal populations of BMSCs were found to express varying levels of these four RTKs. Although not absolutely predictive of a particular clone's ability to support bone formation in the in vivo transplantation assay, it was found that there is relatively high levels of PDGF-R (beta) in bone-forming clones, and relatively high levels of EGF-R in non-bone forming clones, and that the rate of proliferation of bone-forming clones is positively correlated with the amount of bone formed in vivo. Members of the program also collaborated with members of the Molecular Biology of Bones and Teeth program and outside investigators in the establishment of immortalized BMSCs from a patient null for the expression of the estrogen receptor (alpha), the identification of SHOX/PHOG, a transcription factor implicated in skeletal growth in BMSCs, and identification and characterization of human cementoblasts by using an in vivo transplantation system.

## **Molecular Biology of Bones and Teeth**

The objective of the Molecular Biology of Bones and Teeth program, headed by Dr. Marian Young, is to study the function and regulation of matrix proteins found in bones and teeth using a combination of in vitro and in vivo analysis. These proteins play key roles in the metabolism of these tissues. The genes that have been studied are biglycan (BGN) and bone sialoprotein (BSP), both of which are highly expressed in bones and teeth. A major impediment for the study of human gene function and regulation has been the extreme inefficiency of DNA transfer into human, non-transformed cultured cells. In order to devise new methods to overcome this hurdle, two adenoviral-based procedures were tested using bone marrow stromal cells and trabecular



bone cells, both derived from human skeletal material in collaboration with members of the Skeletal Biology program. Adenoviruses containing beta-galactosidase recombinant genes showed substantial gene transfer (10,000x over control) indicating that adenovirus based methods are ideal for these unique cell types. Adenoviruses additionally modified with polylysine were also tested and it was found that they transferred genes into multilayered, highly differentiated non-dividing bone cells, also with high efficiency. This latter procedure has numerous advantages in that it is rapid, simple, and does not require incorporation of transgenes into the viral genome. To examine the function of matrix proteins in vivo, *bgn*-deficient mice were generated, and characterized in collaboration with other members of the Branch. While apparently normal at birth, these mice display a phenotype characterized by a reduced growth rate and failure to achieve peak bone mass due to the absence of *bgn*. This is the first report that deficiency of a non-collagenous extracellular matrix protein leads to a skeletal phenotype that is marked by low bone mass which becomes more obvious with age. These mice may serve as an animal model to study the role of genetic factors that control peak bone mass and extracellular matrix composition and function in osteoporosis.

### **Matrix Biochemistry**

The Matrix Biochemistry program, headed by Dr. Larry Fisher, has focused on structure-function studies of the non-collagenous proteins of bones and teeth, with particular emphasis on matrix protein-protein or matrix protein-cell interactions. It is highly likely that both the assembly of the matrix and its subsequent mineralization is controlled by cells via the use of some of these non-collagenous proteins. A study was completed showing that the small proteoglycan, decorin, and very likely its homolog, biglycan, is endocytosed by cells using the Leu125-Val230 portion of the protein(s). Additional work on the biglycan promoter has lead to hypothesis that the transcription factor, c-Krox, is important in the regulation of this important molecule, and the phenotype of the biglycan knockout animal was also characterized in collaboration with other members of the Branch. Another abundant protein in the mineralized matrices of bones and dentin is a protein discovered by this group several years ago, bone sialoprotein (BSP). This phosphorylated, sulfated glycoprotein binds to integrins, particularly the vitronectin receptor, through its RGD tripeptide. Although BSP in adults is generally limited to the skeleton, work with collaborators has shown that this molecule is likely to be a very good marker for the appearance of many osteotropic cancers including breast, lung, thyroid and prostate. Current efforts are aimed at developing useful BSP assays for these cancers. Working with members of the Skeletal Biology and Skeletal Clinical Studies programs, the group has contributed to the genetic mutation analysis of human McCune-Albright Syndrome marrow stromal cells and their role in the development of fibrous dysplastic bone. Collaborative work with the enamel matrix protein, tuftelin, has continued with the description of the human protein and gene. This highly conserved protein is on chromosome 1 and is currently a candidate gene for some cases of amelogenesis imperfecta.

### **Mineral Chemistry and Structure**

The Mineral Chemistry and Structure program, headed by Dr. David Eanes, continued to focus its research effort on the study of calcium phosphate salts, with particular emphasis on their



chemistry and structure, on in vitro model systems designed to more fully elucidate the various physicochemical factors that control their formation in vivo, and on developing uses for these salts in dental and biomedical materials applications. Previous work suggested that methacrylate-based composites with ACP as filler could possibly find uses as mineralizing agents in clinical dentistry. It was found that the mechanical strength of ACP-filled methacrylate composites was comparable to that of commercial cavity lining materials. These findings, together with the unique ability of ACP composites to release calcium and phosphate ions that possibly could stimulate the formation of reparative dentin, suggest that ACP composites may make excellent lining materials for protecting the pulp against restoration-induced chemical irritations. Also, methods were developed for synthesizing by hydrolysis-condensation reactions of trialkoxyorganosilanes, a variety of oligomeric organofluorosilsesquioxanes. These highly fluorinated organofluorosilsesquioxanes have potential use in dentistry as well. Another major effort is being directed toward delineating the effects that solution state has on the formation, growth, and textural properties (size, shape) of calcium phosphate salts, especially apatite. Findings revealed that carbonate-induced proliferation of new crystals could be a significant factor in controlling the size of apatite crystals in skeletal tissues. Fluoride and magnesium ions were found to partially offset the repressive effect carbonate had on primary crystal growth. Fluoride ions also directly affected crystal growth. In other studies, the calcium salt of glutaryl-bisphosphonate (GIBPD), a new bisphosphonate that has potential clinical use in treating calcium-related bone disorders, was characterized. The near-perfect lattice matches found between the CaGIBPD crystal faces and the major crystal faces of hydroxyapatite indicate that epitaxial growth of CaGIBPD can occur on the apatitic surface. This may be a mechanism by which GIBPD could clinically affect biomineralization processes.

## **Skeletal Clinical Studies**

A major goal of the Skeletal Clinical Studies program, currently directed by Dr. Pamela Gehron Robey, is to elucidate the role of osteogenic cells in the generation of a variety of skeletal dysplasias. Under Protocol #97-DK-0055, it was found that the metabolic activity of bone-forming cells is altered by a number of known mutations. In fibrous dysplasia of bone (FD) and in McCune-Albright Syndrome (MAS) which presents with severe fibrous dysplasia, there are missense mutations of the G protein, Gs alpha, leading to overproduction of cAMP. It was found that this protein is dramatically upregulated as bone marrow stromal cells (BMSCs) mature into osteoblasts, and the effects of the mutations are manifested by abnormal cell-cell (hyperosteocytic bone), cell-matrix interactions (cellular retraction), and the formation of an abnormal bone matrix. A spectrum of bone lesions associated with such mutations was identified and recognizable as three primary, but distinct, histological patterns. The data emphasize the non-random (site-specific) variability of FD histopathology in patients carrying activating mutations of the Gs alpha gene, and provide additional evidence for the occurrence of Gs alpha mutations in cases of FD other than typical MAS. Using an in vivo transplantation system, it was found that populations containing mutated BMSCs leads to the recapitulation of FD formation in immunocompromised mice, representing a novel model system for determination of the pathophysiology of the disease and development of new therapeutic strategies. Furthermore, the study demonstrated the need for both normal and mutated cells (somatic mosaic) for formation of a FD lesion. From these studies, several clinical protocols for

the study and treatment of patients with FD have been approved (98-D-0145, 98-D-0146 and 99-D-0003) and patient recruitment is about to begin. Another goal is to examine the ability of ex vivo expanded BMSCs (obtained under Protocol 94-DR-0188), to regenerate normal bone tissue. Full thickness osseous defects (5 mm) were prepared in the cranium of immunocompromised mice and were treated with gelatin sponges containing murine alloplastic bone marrow stromal cells. Cultured bone marrow stromal cells transplanted within an appropriate vehicle resulted in osteogenesis that repaired greater than  $99.0\% \pm 2.20\%$  of the original surgical defect within two weeks. A pre-IND application for use of this technology in human patients with calvarial defects has recently been reviewed by FDA, and final approval is pending “proof of principle” studies in dogs, which are due to be analyzed in the winter of 1999.

## **CRANIOFACIAL AND SKELETAL DISEASES BRANCH 1998 BIBLIOGRAPHY**

Ankrom MA, Patterson JA, Davis PY, Vetter UK, Blackman MR, Gehron Robey P, Shapiro JR, Fedarko, FS. Age-related changes in human estrogen receptor levels and function. *Biochem J* 1998;333:787-94.

Antonucci JM, Fowler BO, Stansbury JW. Facile syntheses of oligomeric organosilsesquioxanes. *Polymer Preprints* 1998;39:810-1.

Bellahcène A, Maloujahmoum N, Fisher LW, Pasorino H, Tagliabue E, Menard S, Castronovo V. Expression of bone sialoprotein, a bone matrix phosphoprotein, in human lung cancer. *Calcif Tissue Int* 1997;61:183-8.

Bellahcène A, Albert V, Pollina L, Basolo F, Fisher LW, Castronovo V. Ectopic expression of bone sialoprotein in human thyroid cancer. *Thyroid* 1998;8:637-41.

Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM, Gehron Robey P. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and GS alpha-mutated skeletal progenitor cells. *J Clin Invest* 1998;101:1737-44.

Boskey A, Xu T, Paget D, Young MF. Biglycan knockout mice show altered biomineralization. *Trans Orthopaed Res Soc* 1998;23:14.

Deutsch D, Palmon A, Dafni L, Mao ZK, Leytin V, Young M, Fisher LW. Tuftelin: aspects of protein and gene structure. *Eur J Oral Sci*, 1998;106:315-23.

Dieudonne S, Xu T, Chou J, Kuznetsov S, Satomura S, Mankani M, Fedarko NS, Smith EP, Gehron Robey P, Young MF. immortalization and characterization of bone marrow stromal cells from a patient with loss of function mutation in the estrogen receptor alpha gene. *J Bone Miner Res*, 1998;13:598-608.

Eanes ED. Amorphous calcium phosphate: thermodynamic and kinetic considerations. In: Amjad Z, ed. Calcium Phosphates in Biological and Industrial Systems. Boston, MA: Kluwer Academic Publishers, 1998;21-39.

Eanes ED, Hailer AW. The effect of fluoride on the size and morphology of apatite crystals grown from physiologic solutions. *Calcif Tissue Int* 1998;63:250-7.

Ellison, JW, Wardak Z, Young MF, Gehron Robey P, Laig-Webster M, Chiong, W. PHOG, a candidate gene for involvement in the short stature of Turner syndrome. *Human Mol Genet* 1997;6:1341-7.

Erlacher L, McCartney J, Piek E, Ten Dijke P, Yanagishita M, Oppermann H, Luyten FP. Cartilage-derived morphogenetic proteins and osteogenic protein-1 differentially regulate osteogenesis. *J Bone Miner Res* 1998;13:383-92.

Erlacher L, Ng CK, Ullrich R, Krieger S, Luyten FP. Presence of cartilage-derived morphogenetic proteins in articular cartilage and enhancement of matrix replacement in vitro. *Arthritis Rheum* 1998;41:263-73.

Fisher LW. Biglycan (BGN); Bone sialoprotein (BSP); and Decorin (DCN). In: Kreis T, Vale R, eds. Guidebook to the Extracellular Matrix and Adhesion Proteins (Revised). Oxford, UK: Oxford University Press, 1998, in press.

Gehron Robey P, Bianco P. The collagenous and non-collagenous proteins of cells in the osteoblastic lineage. In: Zaidi M, ed. The Molecular and Cell Biology of Bone. Greenwich, CN: JAI Press, 1998, in press.

Gehron Robey P, Bianco P. Cellular mechanisms of age-related bone loss. In: Rosen C, Glowacki J, Bilezikian JP, eds. Aging and the Human Skeleton. San Diego, CA: Academic Press, 1998, in press.

Gehron Robey P. Bone matrix proteins. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. New York, NY: Lippincott Press, 1998, in press.

Grzesik WJ, Kuznetsov SA, Uzawa K, Mankani M, Gehron Robey P, Yamauchi M. Normal human cementum-derived cells: Isolation, clonal expansion and in vitro and in vivo characterization. *J Bone Miner Res*, 1998, in press.

Hausser H, Schonherr E, Muller M, Liszio C, Bin Z, Fisher LW, Krecse H. Receptor-mediated endocytosis of decorin: involvement of leucine-rich repeat structures. *Arch Biochem Biophys* 1998;349:363-70.



- Heegaard A-M, Gehron Robey P, Vogel W, Just W, Windom RL, Scholler J, Fisher LW, Young MF. Functional characterization of the human biglycan 5'-flanking DNA and binding of the transcription factor c-Krox. *J Bone Miner Res*, 1997;12:2050-60.
- Hirst KL, O'Connor K, Young MF, Dixon MJ. Cloning and expression analysis of the bovine dentin matrix acidic phosphoprotein gene. *J Dental Res* 1997;76:754-60.
- Hoang BH, Thomas JT, Abdul-Karim FW, Correia KM, Conlon RA, Luyten FP, Ballock RT. Expression pattern of two Frizzled-related genes, *Frzb-1* and *Sfrp-1*, during mouse embryogenesis suggests a role for modulating action of Wnt family. *Dev Dynam* 1998;212:364-72.
- Krebsbach P, Mankani M, Kuznetsov S, Satomura K, Gehron Robey P. Repair of craniotomy defects using bone marrow stromal cells. Transplantation 1998, in press.
- Krebsbach PA, Kuznetsov SA, Bianco P, Gehron Robey P. Bone marrow stromal cells: characterization and clinical application. *Crit Rev Oral Biol Med* 1998, in press.
- Kuznetsov SA, Krebsbach PH, Emmons RVB, Rowe DW, Gehron Robey P. Creation of a new bone and hematopoietic microenvironment in vivo by cultured marrow stromal fibroblasts: comparison of mouse and human models. In: Greenberger, J., ed. *Proceedings of the Keystone Conference on the Bone Microenvironment*, 1998, in press.
- Kuznetsov SA, Krebsbach PH, Satomura K, Kerr JA, Riminucci M, Benayahu D, Gehron Robey, P. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. *J Bone Miner Res*, 1997;12:1335-47.
- Majolagbe A, Gehron Robey P. Skeletogenesis: differentiation of osteoblastic cells in vitro. In: Tuan RS, Lo CW, eds. *Developmental Biology Protocols*. New York, NY: Humana Press Inc., 1998. in press.
- Mankani M, Gehron Robey P. Transplantation of bone forming cells. In: Raisz L, ed. *The Endocrinologist* 1998, in press.
- Mankani M, Gehron Robey P. Bone regeneration and repair. In: Guggenheim B, ed. *Proceedings of the European Research Group for Oral Biology*. Basel, Switzerland: S Karger AG, 1998;116-21.
- Marmary Y, Parlow AF, Goldsmith CM, He X, Wellner RB, Satomura K, Kriete MF, Gehron Robey P, Nieman LK, Baum, BJ. Construction and in vivo efficacy of a replication-deficient recombinant adenovirus encoding murine growth hormone. *Endocrinology* 1998, in press.
- Mathew M, Fowler BO, Breuer E, Golomb G, Alferiev IS, Eidelman N. Synthesis, characterization, and crystal structure of dicalcium glutaryl-bisphosphonate dihydrate: a

covalently pillared layer structure with the potential for epitaxial growth on hydroxyapatite. *Inorg Chem* 1998, in press.

Park MS, Eanes ED, Antonucci JM, Skrtic D. Mechanical properties of bioactive amorphous calcium phosphate/methacrylate composites. *Dental Materials* 1998, in press.

Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P. Fibrous Dysplasia of bone in the McCune-Albright syndrome: Abnormalities in bone formation. *Am J Pathol* 1997;151:1587-1600.

Riminucci M, Liu B, Corsi A, Shenker A, Spiegel AM, Gehron Robey P, Bianco P. The histopathology of fibrous dysplasia of bone related to activating mutations of the Gs alpha gene: varied site-specific patterns and recurrent histological hallmarks. *J Pathol* 1998, in press.

Satomura K, DeRubeis AR, Fedarko NS, O'Connor K, Kuznetsov SA, Rowe D, Young MF, Gehron Robey P. Receptor tyrosine kinase expression in human bone marrow stromal cells. *J Cell Physiol* 1998, in press.

Sommer B, Kuznetsov SA, Gehron Robey P, O'Connell B, Cristiano RJ, Young MF. Efficient gene transfer into normal human skeletal cells using conjugated adenovirus-DNA complexes. *Calcif Tiss Int* 1998, in press.

Van der Pluijm G, Vloedgraven H, Papapoulos S, Lowik C, van der Wee-Pals L, Grzesik WJ, Kerr JM, Gehron Robey P. Attachment characteristics and involvement of integrins in adhesion of breast cancer cells to extracellular bone matrix constituents in vitro. *J Lab Invest* 1997;77:665-75.

Waltregny D, Bellahcene A, van Riet I, Fisher LW, Young MF, Fernandez P, Dewe W, deLeval J, Castronovo V. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. *J Natl Cancer Inst* 1998;90:1000-8.

Xu T, Bianco P, Fisher LW, Longenecker G, Boskey A, Smith E, Goldstein S, Bonadio J, Boskey A, Heegaard A-M, Sommer B, Satomura K, Dominguez PA, Zhao C, Kulkarni AB, Gehron Robey P, Young MF. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. *Nature Genet* 1998;20:78-82.

# GENE THERAPY AND THERAPEUTICS BRANCH

*Bruce Baum*  
*Indu S. Ambudkar*  
*Brian O'Connell*  
*R. James Turner*





## GENE THERAPY AND THERAPEUTICS BRANCH

1998

The Gene Therapy and Therapeutics Branch (GTTB) has 5 principal investigators (PIs), each with a unique research focus, who cooperatively provide a bench to clinic continuum focusing on questions related to salivary gland dysfunction. Indu Ambudkar is Chief of the Secretory Physiology Section (SPS), and is generally studying signal transduction mechanisms operative in salivary glands with a primary interest in  $\text{Ca}^{2+}$  entry pathways of non-excitable cells. Jim Turner is Chief of the Membrane Biology Section (MBS), and is generally addressing ion transport pathways leading to transcellular salt gradient formation in salivary acini, with a main focus on the secretory isoform of the  $\text{Na}^+\text{-K}^+\text{-2Cl}^-$  cotransporter. Bruce Baum is Chief of the Gene Transfer Section (GTS), and has primarily used adenoviral-mediated gene transfer in strategies to repair irradiation-damaged salivary glands and to direct the secretion of transgene products for systemic use. Brian O'Connell is Chief of the Gene Regulation and Expression Unit, (GREU), and is studying the cellular factors and genomic elements modulating salivary cell gene expression in addition to developing a gene transfer strategy to manage azole-resistant mucosal candidiasis. Phil Fox is Chief of the Clinical Investigations Section (CIS), which is focused on the management of patients with primary Sjogren's syndrome (SS). We are a group which believes significant advances in clinical care will only come from understanding biological mechanism. We focus on salivary glands, secretory epithelial tissues with a complex, highly regulated biology.

Neurotransmitter regulation of fluid secretion in salivary glands primarily depends on the activation of  $\text{Ca}^{2+}$  influx. This  $\text{Ca}^{2+}$  influx mechanism in salivary gland, and other non-excitable cells is as yet largely uncharacterized. For many years the SPS has focused its efforts on identifying the molecular component(s) mediating and regulating this  $\text{Ca}^{2+}$  influx process. During this fiscal year SPS studies concentrated in two areas. The first involved a candidate molecule for this pathway, termed Trp, which was recognized initially in drosophila studies. The SPS has demonstrated the presence of two Trp isoforms in salivary epithelial cells via molecular and confocal microscopic methods, and now are assessing their function. The second major study area has involved the electrophysiological characterization of  $\text{Ca}^{2+}$ -dependent  $\text{K}^+$  channel activity in salivary cells. Using this as a tool to study  $\text{Ca}^{2+}$  influx, SPS investigators have shown that the  $\text{Ca}^{2+}$  influx pathway is tightly regulated by the  $[\text{Ca}^{2+}]$  at the site of influx, which in turn is controlled by activity of the intracellular  $\text{Ca}^{2+}$  pump.

Once a salivary acinar cell is stimulated to secrete fluid (via a  $\text{Ca}^{2+}$  mobilizing stimulus) it is the cell's job to generate a transcellular salt ( $\text{NaCl}$ ) gradient to drive the secretion of osmotically obliged water. This involves the activation of several specific ion channels and transporters. The  $\text{Na}^+\text{-K}^+\text{-2Cl}^-$  cotransporter is considered to be a key component of this process. It is thought to be the major  $\text{Cl}^-$  entry pathway in acinar cells and thereby the principal factor in driving the acinar  $\text{Cl}^-$  secretion which ultimately leads to salt and water secretion. The MBS has over the years focused considerable effort in better understanding the functioning and regulation of this cotransporter in salivary acinar cells. Studies during the past year have been directed at understanding the phosphorylation event associated with upregulation of cotransporter activity in response to cAMP mobilizing stimuli. This phosphorylation site has now been localized to an N-

terminal peptide obtained by CnBr digestion. Interestingly, this peptide does not contain a consensus site for cAMP-dependent protein kinase A, suggesting that the signaling cascade following intracellular cAMP production is more complex than originally thought. Additional experiments carried out over the past year indicate that phosphorylation at this site is required for functional activity. Much of the MBS's future efforts will be geared towards understanding the structure/function relationships of the cotransporter and its homologues. To this end they have recently established that the cotransporter exists as a homodimer in the acinar cell membrane and their results suggest that this is due to an interaction between the hydrophobic membrane spanning domains of the protein. In addition the MBS has succeeded in expressing the cotransporter in yeast as a first step in obtaining sufficient quantities of protein for more detailed biochemical and biophysical studies.

Research in the GTS and GREU continued to be directed at clinically-relevant applications of gene transfer to salivary glands. Two specific clinical situations have been targeted by the GTS; the repair of irradiation-damaged salivary glands and growth hormone (GH) deficiency. The GTS has continued to make progress in both projects during this reporting period. For example, we previously showed that administration of a recombinant adenovirus (AdhAQP1) encoding the water channel aquaporin-1 leads to increased fluid secretion from irradiated rat submandibular glands. During this year GTS scientists have shown that AdhAQP1 can be administered to irradiated primate parotid glands without untoward local (salivary) or systemic effect. Further, GTS investigators showed that hAQP1 can be delivered to mouse salivary glands *in vivo* via a recombinant adeno-associated virus (AAV). This offers the possibility that recombinant AAV, which is less immunogenic and allows longer-lived transgene expression than recombinant adenoviruses, can be used clinically with these glands. In the second focus area, the GTS has developed a recombinant adenovirus encoding murine GH. With a dwarf mouse model, this virus (AdCMVmGH) leads to a doubling in animal size within 30 days after a single intramuscular injection and to therapeutic levels of the hormone after a single administration to the submandibular glands.

One of the main deficiencies of *in vivo* gene transfer is the difficulty in achieving stable gene expression. Previous work in the GREU has focused on the attenuation of immunologic responses to adenoviral vectors. Now the GREU has made considerable progress in the development of a novel integrating viral vector. Sequences from a retrovirus were incorporated into a replication-deficient adenoviral vector backbone. The resulting chimera was able to efficiently infect cells *in vivo* and *in vitro*. In addition, the vector demonstrated strong evidence of genomic integration and persistent gene expression. Such a vector would have broad applicability for *in vivo* gene transfer and gene therapy in a variety of dividing and quiescent cell types. The GREU has continued the characterization of salivary acinar cell and ductal cell promoters. Using an *in vitro* model of salivary cell differentiation, studies of the effects of various growth factors and other extracellular matrix components on the induction of salivary amylase have progressed and allowed a better understanding of the pathways that lead to cytodifferentiation. Also the GREU's important studies on the salivary antifungal proteins, histatins, have proceeded in several directions. Adenovirus-mediated expression of histatin 3 in rabbit submandibular saliva was achieved and the recombinant protein was found to be functional *in vitro*. Laboratory experiments with histatin 3 have revealed a specific binding site



for the protein on the *C. albicans* membrane. Binding and translocation of histatin 3 was shown to be necessary for cell death to occur.

During this year, the CIS continued its landmark studies on the natural history and pathogenesis of primary SS, as well as initiating two important clinical trials. The first of these is examining the efficacy of dehydroepiandrosterone (DHEA) to improve the autoimmune status of patients with primary SS, and has achieved >50% enrollment. The second study protocol was just approved and looks at the utility of thalidomide in managing primary SS. Enrollment is set to begin. CIS scientists have also continued to examine immunopathologic mechanisms involved in SS by studying differential cytokine gene expression in subpopulations of cells found in the minor salivary glands (acinar, ductal, lymphoid) of patients and controls. As reported last year, the approach used was a cell-specific microdissection technique coupled with RT-PCR and Southern hybridization. Results have shown that there is abundant cytokine gene expression by epithelial cells in salivary glands of both patients and controls, suggesting their implication in normal salivary gland homeostasis.

Overall, FY98 has been a highly productive year for the GTTB. We continue to make progress bringing innovative clinical management tools, grounded in solid basic science, to benefit patients with salivary gland disorders.

## **GENE THERAPY AND THERAPEUTICS BRANCH 1998 BIBLIOGRAPHY**

Al-Hashimi I, Haghighat N, Fox PC. Salivary electrophoresis in the diagnosis of Sjögren's syndrome. *Oral Surg Oral Med Oral Pathol* 1998; 85:542-47.

Baum BJ. Establishing a proof of principle: an oral application of gene therapy. *J Israeli Dent Assoc* 1998; 15:7-10.

Baum BJ. Re-engineering the function of salivary glands. In: Guggenheim B, Shapiro S., eds. *Oral biology at the turn of the century: misconceptions, truths, challenges and prospects*. Basel: S. Karger, 1998; 247-52.

Baum BJ, Atkinson JC, Baccaglini L, Berkman ME, Brahim JS, Davis C, Lancaster HE, Marmary Y, O'Connell AC, O'Connell BC, Wang S, Xu Y, Yamagishi H, Fox PC. The mouth is a gateway to the body: gene therapy in 21st century dental practice. *J Calif Dent Assoc* 1998; 26:455-60.

Baum BJ, Davis C. Clinical research, dental education, and the NIH clinical research training program. *J Dent Educ* 1998; 62:566-70.

Baum BJ, O'Connell BC. In vivo gene transfer to salivary glands. *Crit Rev Oral Biol Med*, in press.

Baum BJ, Wellner RB. Receptors in salivary glands. In: Garrett JR, Ekstrom J, Anderson LC. Neural mechanisms of salivary secretion. S. Karger, in press.

Chauthaiwale JV, Lockwich TP, Ambudkar IS. Characteristics of a low affinity passive  $\text{Ca}^{2+}$  influx component in rat parotid gland basolateral plasma membrane vesicles. *J Membr Biol* 1998; 162:139-45.

Davis JC Jr, Fessler BJ, Tassioulas IO, McInnes I, Yarboro CH, Pillemer SR, Fleisher TA, Klippel JH, Boumpas DT. High-dose versus low-dose fludarabine in the treatments of patients with severe refractory rheumatoid arthritis. *J Rheumatol* 1998; 25:1694-704.

Delporte C, Baum BJ. Preclinical and biological studies using recombinant adenoviruses encoding aquaporins 1 and 5. *Eur J Morphol* 1997, in press.

Delporte C, Hoque ATMS, Kulakusky JA, Braddon VR, Goldsmith CM, Wellner RB, Baum BJ. Relationship between adenovirus-mediated aquaporin 1 expression and fluid movement across epithelial cells. *Biochem Biophys Res Commun* 1998; 246:584-8.

Delporte C, Miller G, Kagami H, Lillibridge CD, O'Connell BC, Atkinson JC, Baum BJ. Safety of salivary gland-administered replication-deficient recombinant adenovirus in rats. *J Oral Pathol Med* 1998; 27:34-8.

Delporte C, Panyutin IG, Sedelnikova OA, Lillibridge CD, O'Connell BC, Baum BJ. Triplex forming oligonucleotides can modulate aquaporin-5 gene expression in epithelial cells. *Antisense Nucleic Acid Drug Develop* 1997; 7:523-9.

DeNichilo MO, Katz B, O'Connell BC, Yamada KM. Adenovirus-mediated gene delivery of pp125<sup>FAK</sup> into cultured human macrophages deficient in this protein directs p50<sup>CSK</sup> localization to focal contacts and regulated MAP kinase. *J Cell Physiol* 1998, in press.

Evans RL, Turner RJ. Evidence for a physiological role of  $\text{NH}_4^+$  transport on the secretory  $\text{Na}^+$ - $\text{K}^+$ - $2\text{Cl}^-$  cotransporter. *Biochem Biophys Res Comm* 1998; 245:301-06.

Evans RL, Turner RJ. New insights into the upregulation and function of the salivary  $\text{Na}^+$ - $\text{K}^+$ - $2\text{Cl}^-$  cotransporter. *Eur J Morphology* 1997, in press.

Fox PC. Acquired salivary dysfunction: drugs and radiation. *Ann NY Acad Sci* 1998; 842:132-37.

Fox PC, Brennan M, Pillemer S, Radfar L, Yamano S, Baum BJ. Sjogren's syndrome: a model for dental care in the 21st century. *JADA* 1998; 129:719-28.

Fox PC, Grisius MM, Bermudez DK, Sun D. Cytokine mRNA expression in labial salivary glands and cytokine secretion in parotid saliva in Sjögren's syndrome. *Adv Exp Med Biol* 1998; 438:909-16.



Fox PC. Management of dry mouth. *Dent Clin North Am* 1997; 41:863-75.

Fox PC. Saliva and kissing. In: Smith RA, ed. *Encyclopedia of AIDS*. Chicago: Fitzroy Dearborn Publishers, 1998; 318-319:439-40.

Fox PC. Xerostomia and its clinical management: current treatments of xerostomia and salivary hypofunction. *Adv Dent Res*, in press.

Gannot G, Bermudez D, Lillibridge D, Fox PC. Fas and Fas-mediated effects on a human salivary cell line in vitro: a model for immune-mediated exocrine damage in Sjögren's syndrome. *Cell Death Differentiation* 1998; 5:743-50.

Gannot I, Bonner RF, Gannot G, Fox PC, Gandjbakhche AH. Optical simulations of a non-invasive technique for the diagnosis of diseased salivary glands *in situ*. *J Med Physics* 1998; 25:1139-44.

Gniewek RA, Sandbulte C, Fox PC. Comparison of antinuclear antibody testing methods by ROC analysis with reference to disease diagnosis. *Clin Chem* 1997; 43:1987-89.

Grisius MM, Bermudez DK, Fox PC. Salivary and serum IL-6 in primary Sjögren's syndrome. *J Rheumatol* 1997; 24:1089-91.

Grisius MM, Fox PC. Salivary gland dysfunction and xerostomia. In: Linden RWA, ed. *The Scientific Basis of Eating*. *Frontiers Oral Biol* 1998; 9:156-67.

He X, Goldsmith CM, Marmary Y, Wellner RB, Parlow AF, Nieman LK, Baum BJ. Systemic action of human growth hormone following adenovirus-mediated gene transfer to rat submandibular glands. *Gene Ther* 1998; 5:537-41.

He X, Kuijpers GAJ, Goping G, Kulakusky JA, Zheng C, Delporte C, Tse C-M, Redman RS, Donowitz M, Pollard HB, Baum BJ. A polarized salivary cell monolayer useful for studying transepithelial fluid movement in vitro. *Pflugers Archiv* 1998; 435:375-81.

Hirsch RM, Fernandes RJ, Pillemer SR, Hochberg MC, Lane NE, Altman RD, Knowler WC, Bennett PH. Enlarged acetabular labrum in the Pima Indians. *J Rheumatol* 1997; 24:2210-2.

Hirsch RM, Fernandes RJ, Pillemer SR, Hochberg MC, Lane NE, Altman RD, Bloch DA, Knowler WC, Bennett PH. Hip osteoarthritis prevalence estimates by three radiographic scoring systems. *Arthritis Rheum* 1998; 41:361-68.

Hirsch R, Lin J-P, Scott WW Jr, Ma LD, Pillemer SR, Kastner DL, Jacobsson LTH, Bloch DA, Knowler WC, Bale SJ. Rheumatoid arthritis in the Pima Indians: the intersection of epidemiologic, demographic and genealogic data. *Arthritis Rheum* 1998; 41:1464-69.

Kagami H, Atkinson JC, Michalek SM, Handelman B, Yu S, Baum BJ, O'Connell BC. Repetitive adenovirus administration to the parotid gland: role of immunological barriers and induction of oral tolerance. *Hum Gene Ther* 1998; 9:305-13.

Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Humnder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum* 1998; 41:778-99.

Liu X, O'Connell AC, Ambudkar IS.  $\text{Ca}^{2+}$ -dependent inactivation of a store-operated  $\text{Ca}^{2+}$  current in human submandibular gland cells. *J Biol Chem*, 1998, in press.

Liu X, Rojas E, Ambudkar IS. Regulation of  $\text{K}_{\text{Ca}}$  current by store-operated  $\text{Ca}^{2+}$  influx depends on internal  $\text{Ca}^{2+}$ -release in HSG cells. *Am J Physiol: Cell Physiol* 1998; 275:C571-C580.

Lockhart PB, Fox PC, Gentry AC, Acharya R, Norton HJ. Pilot study of controlled release pilocarpine in normal subjects. *Oral Surg Oral Med Oral Pathol* 1996; 82:517-24.

Long LR, Pillemer SR, Lawrence RC, Goh G-H, Neve L, Thoma GR. WebMIRS: Web-based medical information retrieval system. *Proceedings of SPIE Storage and Retrieval for Image and Video Databases IV*, San Jose, CA, 1998; 3312:392-403.

Mannes, AJ, Caudle, RM, O'Connell, BC, Iadarola, MJ. Adenoviral gene transfer to spinal cord neurons: intrathecal vs. intraparenchymal administration. *Brain Res* 1998; 793:1-6.

Marmary Y, Parlow AF, Goldsmith CM, He X, Wellner RB, Satomura K, Kriete MF, Robey PG, Nieman LK, Baum BJ. Construction and in vivo efficacy of a replication-deficient recombinant adenovirus encoding murine growth hormone. *Endocrinology*, 1998, in press.

Martens PB, Pillemer SR, Jacobsson LTH, O'Fallon WM, Matteson EL. Survivorship in a population based cohort of patients with Sjogren's syndrome, 1976-1992. *Arthritis Rheum*, in press.

Meehan SM, Wu AJ, Kang EC, Sakai T, Ambudkar IS. Interferon- $\gamma$  induces a decrease in the intracellular calcium pump in a human salivary gland cell line. *Am J Physiol: Cell Physiol* 1997; 273:C2030-C2036.

Moore-Hoon ML, Turner, RJ Increased expression of the secretory  $\text{Na}^{+}\text{-K}^{+}\text{-2Cl}^{-}$  cotransporter with differentiation of a human intestinal cell line. *Biochem Biophys Res Comm* 1998; 244:15-9.

Moore-Hoon ML, Turner RJ. Molecular and topological characterization of the rat parotid  $\text{Na}^{+}\text{-K}^{+}\text{-2Cl}^{-}$  cotransporter. *Biochim Biophys Acta* 1998; 1373: 261-9.

- Moore-Hoon ML, Turner RJ. Molecular characterization of the cation-chloride cotransporter family. *Eur J Morphology*, 1998, in press.
- Nagler R, Baum BJ, Miller G, Fox PC. Long-term effects of single dose regional head and neck irradiation in the rat. *Archs Oral Biol* 1998; 43:297-303.
- O'Connell AC, Lillibridge CD, Zheng C, Baum BJ, O'Connell BC, Ambudkar IS.  $\gamma$ -Irradiation-induced cell cycle arrest and cell death in a human submandibular cell line: effect of E2F1 expression. *J Cell Physiol*, 1998, in press.
- O'Connell AC, Redman RS, Evans, RL, Ambudkar IS. Irradiation-induced progressive decrease in fluid secretion in rat submandibular glands is related to decreased acinar volume and not impaired calcium signaling. *Radiat Res*, 1998, in press.
- O'Connell BC, Lillibridge CD, Ambudkar I, Kruse D. Somatic gene transfer to salivary glands. *Ann NY Acad Sci* 1998; 842:171-80.
- O'Connell BC, Redman RS, Zheng C. In vivo use of adenoviral vectors: effects on salivary gland structure. *Eur J Morphol*. 1997, in press.
- Pillemer S. The neuroscience and endocrinology of fibromyalgia: Introduction. *J Musculoske Pain*, in press.
- Pillemer S. The neuroscience and endocrinology of fibromyalgia: chronic pain segment. *J Musculoske Pain*, in press.
- Pillemer S. The neuroscience and endocrinology of fibromyalgia: neuroendocrine segment. *J Musculoske Pain*, in press.
- Pillemer S. The neuroscience and endocrinology of fibromyalgia: sleep segment. *J Musculoske Pain*, in press.
- Pillemer S. The neuroscience and endocrinology of fibromyalgia: concluding remarks. *J Musculoske Pain*, in press.
- Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. *Arthritis Rheum* 1997; 40(11):1928-39.
- Sommer B, Kuznetsov SA, Gehron Robey P, O'Connell BC, Cristiano RJ, Young MF. Efficient gene transfer into normal human skeletal cells using recombinant press adenovirus and conjugated adenovirus-DNA complexes. *Calc Tissue Int*, 1998, in press.
- Sun D, Emmert-Buck MR, Fox P. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjögren's syndrome. *J Autoimmunity*, in press.

Turner RJ, Paulais M, Valdez IH, Evans RL, Fox PC. Ion transport and signaling in human labial glands. *Arch Oral Biol*, in press.

Tuttleman M, Pillemer S, Tilley B, Fowler S, Buckley L, Alarcón G, Trentham D, Neuner R, Clegg D, Leisen J. Assessment of health status instruments in a rheumatoid arthritis (RA) clinical trial. *J Rheumatol* 1997; 24:1910-15.

Wu AJ, Chen ZJ, Kan EC, Baum BJ. Interferon- $\gamma$  induced JAK2 and STAT1 signalling in a human salivary gland cell line. *J Cell Physiol* 1997; 173:110-14.

Zheng C, Hoffman MP, McMillan T, Kleinman HK, O'Connell BC. Growth factor regulation of the amylase promoter in differentiating salivary gland acinar cells. *J Cell Physiol*, 1998, in press.

ORAL HEALTH  
PROMOTION, RISK FACTORS,  
AND  
MOLECULAR  
EPIDEMIOLOGY BRANCH

*Scott Diehl  
Albert Kingman  
Deborah M. Winn*





## ORAL HEALTH PROMOTION, RISK FACTORS, AND MOLECULAR EPIDEMIOLOGY BRANCH

1998

The Oral Health Promotion, Risk Factors, and Molecular Epidemiology Branch (OHPRFMEB), has continued its scientific focus on molecular genetic epidemiology, analytical epidemiology, and oral health promotion research. In keeping with the NIDCR Strategic Plan, the Branch has been in transition over the past year. Dr. Henning Birkedal-Hansen served as the Acting Branch Chief, and Dr. Scott R. Diehl and Dr. Lawrence Furman served as Acting Deputy Branch Chief during this period of planned restructuring.

The staff of the Health Promotion component of the branch provided special leadership and staffing to the newly evolving Office of Science Policy and Analysis located within the Office of the Director. Dr. Deborah Winn, leader of the Analytical Epidemiology component of the branch, assumed responsibilities in the Office of the Director to help establish the organizational infrastructure for future assessment of the magnitude and distribution of dental, oral and craniofacial diseases and conditions. Over the past year, she and her staff have continued to design and implement of Oral Health Component of the Fourth National Health and Nutrition Examination Survey (NHANES IV) scheduled for field implementation in March of 1999.

The Molecular Genetic Epidemiology component of the branch under the direction of Dr. Scott R. Diehl has continued to conduct family based molecular genetic clinical studies of cleft lip and palate, periodontal disease, Kartagener syndrome, and oral and nasopharyngeal cancers. Strategies include linkage analysis and transmission disequilibrium gene mapping. Dr. Diehl and his staff have continued to provide innovative leadership in large-scale genotyping for highly polymorphic DNA markers including the development of new methods of database management and of improved automated methods for the analysis for complex human genetic disorders.

Dr. Albert Kingman has continued to serve in his capacity as NIDCR's Chief Statistician, conducting data analyses for the NIDCR Amalgam Study, an epidemiological investigation of the potential health risks of exposure to dental amalgam (mercury vapor). As part of his expanded interest in statistical genetics, he began a part time sabbatical with senior researchers in the National Human Genome Research Institute (NHGRI), focused on developing improved methods for conducting linkage analyses of data from genome screens. As part of the transition of the Branch, Dr. Kingman has assisted in formulating and implementing plans for a Biostatistical Core within the Division of Intramural Research that will provide support to all components of the NIDCR.

At the close of this transitional year, the staff and programs of the original Division of Epidemiology and Oral Disease Prevention Program have been successfully assimilated into the Division of Intramural Research and the Office of the Director. The new streamlined DIR Branch will consist of a Molecular Genetic Epidemiology component directed by Dr. Diehl, an Analytical Epidemiology component, directed by Dr. Winn and the Biostatistical Core and related independent research directed by Dr. Kingman. The Oral Health Promotion component and the National survey and related activities previously associated with the branch are being transferred to the Office of the Director. With the refocusing of program emphasis on intramural

research, the OHPRFMEB will be officially renamed in the coming year, and a full time chief recruited for leadership of the branch.

### **Molecular Genetic Epidemiology**

The Molecular Genetic Epidemiology component under the direction of Dr. Scott R. Diehl is conducting studies of oral, dental and craniofacial disorders using strategies such as linkage analysis and transmission disequilibrium gene mapping. Most studies involve molecular assays such as marker polymorphisms or mutation analyses of candidate genes, but some projects are more classical in nature and investigate familial aggregation of diseases and disease-related phenotypes without incorporation of molecular data. Analyses include key behavioral risk factors such as diet, smoking and alcohol consumption, and these are treated both as covariates to disease risk and as genetically heritable phenotypes of interest themselves. Dr. Diehl directs a laboratory engaged in large-scale genotyping for highly polymorphic DNA markers and a statistical and computer group responsible for data management and statistical analyses. Research team members are also responsible for designing and conducting the field studies required for subject recruitment, implemented through collaborations with clinicians throughout the world. Current projects include several studies of oral cancer using both case control designs and families; studies of nasopharyngeal carcinoma using both simplex and multiplex families; studies of non-syndromic cleft lip and palate using both simplex and multiplex families (complemented by a mouse model); studies of early onset periodontitis; a study of immotile cilia syndrome with chronic sinusitis and bronchiectasis. Continuation and completion of the major studies currently in data collection phases will occupy much of the section's available efforts for the next couple years. New clinical initiatives are currently being planned including clinical molecular genetic studies of adult onset periodontitis, and sensitivity and perception of pain. In addition, Dr. Diehl's laboratory will continue to very actively pursue new molecular technologies such as array-based single nucleotide polymorphism (SNPs) for further molecular analyses of the large samples of study subjects currently being recruited, in recognition of the potential for adding substantial power to detect genetic effects for complex disorders that these approaches may provide.

### **Analytical Epidemiology**

The staff of the Analytical Epidemiology component, under the direction of Dr. Deborah Winn, has continued a program of scientific accomplishment and professional service. Their Intramural research includes studies of periodontal health and of oral and pharyngeal cancer. Early onset periodontitis is a disease characterized by a progressive loss of the tooth supporting tissue in adolescents and young adults. A study of adolescents with early onset periodontitis and a control group of adolescents were identified within a population of 14,000 pupils in grades 8 to 12 examined by a national survey of the oral health of US children conducted by NIDCR during the 1986/87 school year. Repeat oral examinations were conducted six year later on these subjects. Discoveries this year include identification of several bacterial species that are more strongly associated with severe EOP than others: *P. gingivalis* and *T. denticola*, and the development of an enhanced clinical classification system for early onset periodontitis. In addition, it was discovered that Beta-glucuronidase in the gingival crevicular fluid of young persons in the study



may be a valuable marker of individuals at higher risk of the generalized form of the disease. Plans are being developed collaboratively with Dr. Diehl to study the FMLP receptor and other genetic markers, to establish a bacterial profile for cases and to examine local and systemic immune factors, associated with this disease.

Oral and pharyngeal cancers are characterized by a) alcohol and tobacco etiology, b) low proportion of tumors identified at an early stage, c) racial differences in stage at presentation, d) racial disparities in survival even controlling for stage, and e) approximately 50% survival rate. These ongoing interrelated studies have as their goal the identification of risk factors for oral and pharyngeal cancer and identification of factors that influence detection of oral cancer or of persons at highest risk of these cancers. One project is the Puerto Rico Oral and Pharyngeal Cancer study in which patients identified through a cancer registry are compared to the general population. The purpose is to identify behavioral, medical, familial, and genetic factors involved in the etiology of this disease. Using the Puerto Rico study population, collaborative investigations with the National Cancer Institute (NCI) are underway to determine how behavior (e.g., tobacco and alcohol consumption, dietary habits), medical and oral conditions, and other factors interact to increase risk of these cancers. The study will help elucidate oral cancer etiology as well as suggest potential opportunities for prevention. Key findings this year include the first evidence that oral and pharyngeal cancer risks decrease with cessation of alcohol consumption, although risks of these cancers remains elevated for up to 20 years after cessation of tobacco or alcohol use. The alcohol dehydrogenase type 3 genotype for slow metabolism of alcohol to acetaldehyde was found to substantially increase the risk of ethanol-related oral and pharyngeal cancer in heavy drinkers. This finding provides further evidence for the carcinogenicity of acetaldehyde.

The SEER/Medicare Linkage Project is focused currently on a determination of patient medical care contacts occurring in the year prior to diagnosis of oral and pharyngeal cancer and the reasons for those contacts. It is hypothesized that relative to persons without cancer, oral cancer patients have more contacts and for more conditions due to the morbidity consequences of high alcohol intake and tobacco use. Answering this question may help suggest approaches to identify the cancers earlier. In a related analysis, we have recently discovered a striking increase over time in the incidence of in-situ carcinomas of the oral cavity, pharynx and larynx.

## **Health Promotion Research**

Activities undertaken by Health Promotion Research staff during the year cover a broad spectrum of oral health related issues and research areas. Research projects focused on: 1) significant but often neglected diseases; for example, early childhood caries and oral cancers, 2) the effects of socioeconomic status and differences in oral health care on the oral health status of racial and ethnic minorities among children, adolescents and adults, 3) limitations of poor/non-poor comparisons of inequalities in oral health status, 4) a study of the prevalence and extent of periodontal conditions in previously diagnosed Type II diabetics as compared with persons not having diabetes, 5) ways of improving approaches to oral health education and health promotion directed at health care professionals and the public, and 6) differential patterns in dental caries by age and implications for the use of dental sealants.

**ORAL HEALTH PROMOTION, RISK FACTORS, AND  
MOLECULAR EPIDEMIOLOGY BRANCH  
1998 BIBLIOGRAPHY**

Albandar JM, Brown LJ, Genco RJ, Löe H. Clinical classification of early-onset periodontitis in adolescents and young adults. *J Periodontol* 1997;68:545-55.

Albandar JM, Brown LJ, Löe H. Clinical features of early-onset periodontitis. *J Am Dent Assoc* 1997;128:1393-99.

Albandar JM, Brown LJ, Löe H. Putative periodontal pathogens in subgingival plaque of young adults with and without early-onset periodontitis. *J Periodontol* 1997;68:973-81.

Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. *J Periodontol* 1998;69, in press.

Albandar JM, Kingman A. Gingival bleeding, gingival recession, and dental calculus in adults 30 years of age and older in the United States, 1988-1994. *J Periodontol* 1998;69, in press.

Albandar JM, Kingman A, Brown LJ, Löe H. Gingival inflammation and subgingival calculus as determinants of disease progression in early-onset periodontitis. *J Clin Periodontol* 1998;5:231-37.

Albandar JM, Kingman A, Lamster IB. Crevicular fluid level of beta-glucuronidase in relation to clinical periodontal parameters and putative periodontal pathogens in early-onset periodontitis. *J Clin Periodontol* 1998;25:630-39.

Beiraghi S, Gillanders E, Miller-Chisholm A, Wang Y-E, Freas-Lutz D, Strom A, Long RE Jr., Mazaheri M, Diehl SR. Localization of Van der Woude syndrome to the 1q41-42 region. *J Dent Res* 1997;76:2847.

Diehl SR, Erickson RP. Genome scan for teratogen-induced clefting susceptibility loci in the mouse: Evidence of both allelic and locus heterogeneity distinguishing cleft lip and cleft palate. *Proc Natl Acad Sci USA* 1997;94:5231-36.

Diehl SR, Bock CJ, Karolyi J, Erickson RP. Identification of teratogen-induced clefting susceptibility genes in the mouse. *J Dent Res* 1997;76:971.

Diehl SR, Wang Y-F, Beck H, Gao Y, Khanna A, Gu X. Interleukin-1 genotypes and risk of early onset periodontitis-A family based study of linkage disequilibrium. *J Dent Res* 1998;77:717.

Diehl SR, Wang Y-F, Brooks CN, Califano, JV, Wang S, Schenkein HA. Linkage disequilibrium of interleukin-1 genetic polymorphisms with early-onset periodontitis. *J Periodontol*, in press.



Harty LC, Caporaso NE, Hayes RB, Winn DM, Bravo-Otero E, Blot WJ, Kleinman DV, Brown LM, Armenian HK, Fraumeni JF Jr., Shields PG. Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancer. *J Natl Cancer Inst* 1997;89:1698-705.

Hayes RB, Bravo-Otero E, Brown LM, Kleinman DV, Harty L, Winn DM. Tobacco and alcohol use and oral cancer in Puerto Rico. *Cancer Causes Control* 1998, in press.

Hu S, Brody CL, Fisher C, Gunzerath L, Nelson ML, Sabol SZ, Sirota LA, Marcus SE, Greenberg BD, Murphy DL, Hamer DH. Cigarette smoking and cessation are influenced by an interaction between the serotonin transporter gene and neuroticism. *Nat Med* 1998, in press.

Kingman A, Albertini TF, Brown LJ. Mercury concentrations in urine and whole blood associated with amalgam exposure in a U.S. military population. *J Dent Res* 1998;77: 23-31.

Reynolds JE, Meyer JM, Landa B, Stevens CA, Amos KS, Israel J, Marazita M, Bodurtha J, Nance WE, Diehl SR. Analysis of variability of clinical manifestations in Waardenburg syndrome. *Am J Med Gen* 1997;57:541-47.

Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S, Sirota LA, Marcus SE, Greenberg BD, Lucas FR, Benjamin J, Murphy DL, Hamer DH. A genetic association for cigarette smoking behavior. *Health Psychol* 1998, in press.

Selwitz RH, Nowjack-Raymer R, Kingman A, Driscoll WS. Dental caries and dental fluorosis among schoolchildren who were lifelong residents of communities having either low or optimal levels of fluoride in drinking water. *J Pub Health Dent* 1998;58:28-35.

Sonnier K, D'Alesandro M, Gu X, Diehl S, Miller G. Association of superantigens in the development of advanced periodontitis. *J Dent Res* 1997;76:3176.

Streckfus CF, Baur U, Brown LJ, Bacal C, Metter EJ, Nick T. Effects of estrogen status and aging on salivary flow rates. *Gerontology* 1998;4:32-9.

Winn DM. Epidemiology of cancer and other systemic effects associated with the use of smokeless tobacco. *Adv Dent Res* 1997;11:313-21.

Winn DM, Diehl SR, Horowitz AM, Gutkind S, Sandberg AL, Kleinman DV. Scientific progress in understanding oral and pharyngeal cancers. *J Am Dent Assoc* 1998;129:713-18.

Winn DM, Sandberg AL, Horowitz AM, Diehl SR, Gutkind S, Kleinman DV. Reducing the burden of oral and pharyngeal cancers. *Calif Dent Assoc J* 1998;26:445-54.



# ORAL INFECTION AND IMMUNITY BRANCH

*Sharon M. Wahl*  
*John Cisar*  
*Jerry Keith*  
*Paul Kolenbrander*  
*Steve Leppla*  
*Abner Notkins*  
*Nick Ryba*  
*Reuben Siraganian*  
*John Thompson*





## ORAL INFECTION AND IMMUNITY BRANCH

### 1998

The Oral Infection and Immunity Branch (OIIB) experienced a highly productive year with new collaborative efforts to build on our strengths and to integrate our diverse research portfolio. A new clinical endeavor, the Clinical Investigations in Infectious and Autoimmune Diseases Program, was initiated, underscoring our commitment to the transition from our basic through translational to clinical research. In a short time our inaugural clinical protocol received IRB approval and began to accrue patients.

Our multiple interactions with the extramural community have enabled members of the Branch to advance science and share our research findings through participation in national and international meetings, invitations to speak, chair and organize meetings and symposia throughout the world, and serve on boards of national/international foundations and organizations (Society of Leukocyte Biology, FAES, National Disease Research Interchange, Paul Ehrlich Foundation, March of Dimes Foundation). Beyond participating in NIDR's 50<sup>th</sup> Anniversary Celebration, OIIB members were invited to represent NIDR at the 10<sup>th</sup> Anniversary of the Dental Research Program in Ljubljana, Slovenia and at the 50<sup>th</sup> Anniversary of the School of Dentistry, University of Alabama at Birmingham. Editorial board responsibilities on *Journal of Immunology*, *Journal of Experimental Medicine*, and other prestigious journals further attest to the stature of our Senior Investigators. In additional recognition, substantial outside funding rewarded OIIB's productive programs in anthrax biology and diabetes research and two NIDCR, DIR Emerging Scientific Opportunities Grants have been awarded.

Biweekly meetings of the Branch Chief and Senior Investigators maintain open lines of communication, providing a forum for administrative and programmatic issues and to facilitate Branch activities. In our continuing efforts to facilitate interactions of the Branch at all levels, monthly poster sessions with refreshments, social and scientific interchange were held, followed by a Meet the Senior Investigators Lecture Series, all orchestrated by the OIIB Seminar Coordinating Committee together with the OIIB Quality of Life Committee.

Senior Investigators in the OIIB have made important research progress, including exciting breakthroughs in the past year, and our FY 98 Bibliography lists nearly 100 publications. Among these are reports in *Science*, *Proceedings of the National Academy of Science*, *Journal of Biological Chemistry*, *Journal of Clinical Investigation*, *EMBO*, *Journal of Experimental Medicine*, and *Neuron*. Our research portfolio continues to focus on the molecular and biochemical diversity of infectious pathogens, on characterizing innate and adaptive immune responses, and on dissecting pathogen-host interactions, and several of these areas are highlighted in this Annual Report.

The establishment and persistence of bacterial microcommunities is dependent on specific interactions between different organisms that inhabit the biofilm. Co-aggregations, microbial cell-to-cell interactions among genetically distinct partner strains, are mediated by complementary cell surface components on the participating bacterial partners. Bacteria also may recognize host epithelial cells by some of these same surface components. Oral streptococci

play a critical role in the normal microbial ecology of the human oral cavity by functioning as primary colonizers of hard tissue surfaces. Members of this group also are the leading cause of subacute bacterial endocarditis and dental caries. Characterizing biofilms formed with oral streptococci and other early colonizers continues to aid in understanding the biofilm community structure that forms in advance of destructive periodontal disease and serves as a loading dock for other organisms. In this regard, OIIB investigators provided the first evidence that the *sca* operon in *Streptococcus gordonii* encodes a high-affinity Mn<sup>2+</sup> transporter that appears to be necessary both for growth of cells in low Mn<sup>2+</sup> environments and for DNA-mediated transformation. The putative Mn<sup>2+</sup> binding lipoprotein ScaA, which is inducible under Mn<sup>2+</sup> - limiting conditions, would thus provide a vital mechanism for the acquisition of Mn<sup>2+</sup> by streptococci for growth and survival in the human host. Mutagenesis studies of another operon, the *dlt* operon, of *S. gordonii* revealed that D-alanylation of lipoteichoic acid was critical in adherence, genetic exchange and cell septation. Continued characterization of the streptococcal structurally-related cell wall polysaccharides, recognized by adhesins of other bacteria, involves collaborations with TIGR and will be greatly facilitated by the *S. gordonii* genomic data base. The prevalence and increase in numbers of microorganisms which bind to streptococci, particularly the Gram-negative anaerobic fusobacteria, are hallmarks of the progression of gingivitis and other periodontal diseases. Fusobacteria, in turn, may provide a binding site and reservoir for *H. pylori*, which is then transported to other mucosal sites. In *S. pneumoniae*, genetic mutations provide the basis for the evolution of multi-drug resistance organisms. Trimethoprim resistance was traced to an altered chromosome-encoded dihydrofolate reductase and optochin resistance is the result of a single amino acid mutation of the ATPase gene.

In important new studies, investigators in OIIB have shown that the major virulence factor of *Bacillus anthracis*, the lethal factor protein, is a metalloprotease. Lethal factor which is released as *B. anthracis* spores germinate, cleaves and inactivates mitogen activated protein kinase kinase (MAPKK) to disrupt a central cellular signal transduction pathway involved in cell growth and differentiation. These findings provide a new focal point to develop rational strategies to block lethal factor proteolytic activity and inhibit anthrax toxicity.

Another virulent microbe, HIV, employs other unique genetic strategies to cause infection and disease in its hosts. HIV can influence expression of its requisite co-factor, the CCR5 receptor, in host cells of monocytic lineage and also takes advantage of the ability of *Mycobacterium avium* to enhance the CCR5 receptor. *M. avium* is a frequent opportunistic infection (OI) in immunosuppressed individuals and has recently been shown by OIIB staff to activate the transcription factor, NF- $\kappa$ B. NF- $\kappa$ B mediates the transcription of multiple pro-inflammatory molecules, at least two of which, TNF $\alpha$  and CCR5, increase host cell vulnerability to HIV. Thus, there appears to be a reciprocal regulation between HIV and opportunistic infections such as *M. avium*, emphasizing that treating OI may not only inhibit OI-induced pathology, but also limit the viral burden.

How the host responds to these and other mucosal pathogens as well as to other environmental and endogenous stimuli is the focus of several Senior Investigators in the Branch. Fascinating new studies delineating signaling circuits in the olfactory system have emerged as prototypes for signal transduction pathways, in general. In this regard, efforts have focused on characterization



of the newly identified multigene family of pheromone receptors in the vomeronasal organ of rodents. This family contains as many as 100 genes, and these putative pheromone receptors have related large N-terminal extracellular domains that appear to be the site of ligand binding. Receptor genes are expressed at high levels in small sub-populations of vomeronasal neurons and the one neuron-one receptor model provides a molecular logic for the discrimination of pheromones. However, different sub-families have distinct but overlapping expression patterns within the vomeronasal epithelium, indicating a link between the choice of which receptor is expressed by a vomeronasal neuron and the location of that neuron within the epithelium. The neurons in the vomeronasal epithelium are unusual in that they turnover throughout life, being replaced by division, differentiation of stem cells, and continuous migration of neurons towards the center of the epithelium. These observations emphasize a need for coordinate expression of receptor sub-families and migratory guidance molecules.

The inflammatory response involves the accumulation of extracellular matrix proteins at sites of injury where leukocytes migrate and release an array of mediators. Among these leukocytes, basophils and mast cells have surface adhesion receptors (integrins) that are involved in their binding to other cells or to the extracellular matrix. Such integrin mediated adherence of cells to fibronectin stimulates cell spreading and generates intracellular signals, including tyrosine phosphorylation of proteins such as the focal adhesion kinase, pp125<sup>FAK</sup> (FAK), with enhanced histamine secretion. FAK also becomes tyrosine phosphorylated in response to the activation of various receptors including the high affinity IgE-receptor (Fc $\epsilon$ RI). Transfection of FAK into FAK-deficient mast cells reconstituted their defective secretion and histamine release. As the signaling pathways initiated by immune receptors on lymphocytes and mast cells are related, FAK may play a similar role in their signal transduction. In RBL-2H3 mast cells, tyrosine phosphorylation of several proteins occurs after aggregation of Fc $\epsilon$ RI, although the receptor itself has no kinase activity. New insights into the role of several of the protein tyrosine kinases involved in this intracellular signal transduction have been revealed this past year. Besides FAK, pyk2 and Syk appear critical. In Syk-deficient cells, aggregation of Fc $\epsilon$ RI induced no histamine release and no detectable increase in total cellular protein tyrosine phosphorylation. By transfection, stable expression of Syk signaling was restored. Syk also appears to be critical for cytoskeletal and shape changes.

Autoimmune diseases, often associated with dysregulated signalling events, are characterized by loss of self-tolerance and may lead to destruction of host tissues. Although genetically based, it is difficult to predict the emergence of these often devastating diseases. Important new studies in the OIIB have identified predictive markers for the development of insulin dependent diabetes mellitus (IDDM). Starting with a cDNA subtraction library, 5 new genes were identified, two of which have particular significance in IDDM. IA-2 and IA-2 $\beta$  which are protein tyrosine phosphatases are major autoantigens and induce the formation of autoantibodies which can be detected years before the development of clinical disease. Individuals with antibodies to IA-2 together with glutamic acid decarboxylase (GAD) have a 50% or greater likelihood of developing IDDM within 5 years. New clinical assays are being developed in conjunction with CDC and WHO to screen the general population for susceptible individuals which will provide opportunities for intervention.

In addition to predicting autoimmune disease, efforts in the Branch have focused on approaches for the treatment of autoimmune and infectious diseases. Taking advantage of an experimental model of arthritis triggered by Group A streptococcal cell wall (SCW) peptidoglycan-polysaccharide complexes, investigators have provided the first evidence that erosive arthritis can be suppressed through TGF- $\beta$  gene therapy. Intramuscular administration of plasmid DNA encoding TGF- $\beta$  prior to the administration of arthritogenic SCW, but also after the onset of clinical symptoms, dramatically altered the course of disease. In other studies, the potent immunosuppressive activities of TGF- $\beta$  were also found to be instrumental in the mediation of oral tolerance. In these experiments, which provide the first evidence that a non-self antigen, in this case, SCW, can induce therapeutic oral tolerance, arthritis could be blocked even when oral administration of the antigen was not initiated until later in the disease. The timing was critical, however, providing important information as to delivery kinetics of oral antigens in human disease.

Infectious disease remains the world's leading cause of death and as the OIIB continues to integrate its research portfolio and to develop its clinical program, the Branch will address the challenges of emerging and re-emerging infections, antibiotic resistance, the potential inappropriate use of micro-organisms, infectious links to autoimmunity and therapeutic interventions.

#### **ORAL INFECTION AND IMMUNITY BRANCH 1998 BIBLIOGRAPHY**

Andersen RN, Lunsford RD, Kolenbrander PE. Determination of the transcript size and start site of the putative sca operon of *Streptococcus gordonii* ATCC 51656 (formerly strain PK488). *Adv Exp Med Biol* 1997;418:657-60.

Andersen RN, Ganeshkumar N, Kolenbrander PE. *Helicobacter pylori* adheres selectively to *Fusobacterium* spp. *Oral Microbiol Immunol* 1998;13:51-4.

Ashcroft G, Wahl SM. Bidirectional regulation of macrophages by TGF- $\beta$ . *Res Immunol* 1998;148, in press.

Chan J, Wahl SM. Mononuclear phagocytes in rheumatoid synovium. In: Tsokos G, ed. *Molecular Rheumatology*. Totowa, NJ: The Humana Press Inc. 1998, in press.

Chen WJ, Wahl SM. Manipulation of TGF- $\beta$  levels to control autoimmune and chronic inflammatory diseases. *Res Immunol* 1998, in press.

Chen WJ, Jin W, Wahl SM. Engagement of CTLA-4 induces transforming growth factor  $\beta$  production by murine CD4+ T cells. *J Exp Med* 1998, in press.

Chen WJ, Jin W, Cook M, Weiner HL, Wahl SM. Oral delivery of group A streptococcal cell walls augments circulating TGF- $\beta$  and suppresses SCW arthritis. *J Immunol* 1998, in press.



- Chen ZJ, Wheeler CJ, Shi W, Wu AJ, Yaroboro CH, Gallagher M, Notkins AL. Polyreactive antigen-binding B cells are the predominant cell type in the newborn B cell repertoire. *Eur J Immunol* 1998;28:989-94.
- Cisar JO, Sandberg AL, Reddy GP, Abeygunawardana C, Bush CA. Structural and antigenic types of cell wall polysaccharides from viridans group streptococci with receptors for oral actinomyces and streptococcal lectins. *Infect Immun* 1997;65:5035-41.
- Davenpeck KL, Zagorski J, Schleimer RP, Bochner BS. Lipopolysaccharide-induced leukocyte rolling and adhesion in the rat mesenteric microcirculation: Inhibition by dexamethasone and roles for interleukin-1, tumor necrosis factor, and cytokine-induced neutrophil chemoattractant (CINC). *J Immunol* 1998, in press.
- Donadel G, Marinos N, DeSilva MG, Lu J, Notkins AL, Lan MS. Molecular cloning and characterization of a highly basic protein, IA-4, expressed in pancreatic islets and brain. *Neuroendocrinol* 1997;67:190-96.
- Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland T, Ahn NG, Fukasawa K, Vande Woude G. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. *Science* 1998;280:734-37.
- Duesbery NS, Vande Woude G, Leppla S. How anthrax kills-Response [Letter to the Editor]. *Science* 1998;280:1673-74.
- Ellis TM, Schatz D, Lan MS, Ottendorfer E, Wasserfal C, Notkins AL, Maclaren NK, Atkinson MA, Salisbury PJ, She JX. The relationship between humoral and cellular immunity to IA-2 in IDDM. *Diabetes* 1998;47:566-69.
- Fan J, Marshall JC, Jimenez M, Shek P, Zagorski J, Rotstein OD. Hemorrhagic shock primes for increased expression of cytokine-induced neutrophil chemoattractant in the lung: role of pulmonary inflammation following lipopolysaccharide. *J Immunol* 1998;161:440-47.
- Frazier-Jessen M, McCartney-Francis NL, Wahl SM. Transforming growth factor-beta: a cytokine paradigm. In: Kresina T, ed. *Handbook of Immune Modulating Agents*. New York, NY: Marcel Dekker 1997;121-43.
- Goletz TJ, Klimpel KR, Arora N, Leppla SH, Keith JM, Berzofsky JA. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp-120 anthrax toxin fusion protein. *Proc Nat Acad Sci* 1997;94:12059-64.
- Goletz TJ, Klimpel KR, Leppla SH, Keith JM, Berzofsky JA. Delivery of antigens to the MHC Class I pathway using bacterial antigens. *Human Immunol* 1997;54:129-36.
- Gordon VM, Benz R, Fujii KE, Leppla SH, Tweten RK. *Clostridium septicum* alpha toxin is proteolytically activated by furin. *Infect Immun* 1997;65:4130-34.

Gu M, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. *Vaccine* 1998, in press.

Hale-Donze H, Jackson R, Wahl SM. Quantification of transforming growth factor  $\beta$  isoforms. In: Kruisbeck AM, Margulies DH, Shevach EM, Strober W, eds. *Current Protocols in Immunology*. New York, NY: Greene Publishing Associates and Wiley Interscience 1998, in press.

Hamawy MM, Swieter M, Mergenhagen S, Siraganian RP. Reconstitution of high affinity IgE receptor mediated secretion by transfecting protein tyrosine kinase pp125<sup>FAK</sup>. *J Biol Chem* 1997;272:30498-03.

Hamawy MM, Fischler C, Zhang J, Siraganian RP. Fc $\epsilon$ RI aggregation induces tyrosine phosphorylation of a novel 72 kDa protein downstream of Syk. *Biochem & Biophys Res Comm* 1997;239:670-75.

Hawa MI, Rowe RE, Notkins AL, Pozzili P, Christie MR, Leslie RDG, Lan MS. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. *Diabetes* 1997;48:1270-75.

Jamur MC, Grodzki ACG, Moreno AN, Swain WD, Siraganian RP, Oliver C. Immunomagnetic isolation of rat bone marrow-derived and peritoneal mast cells. *J Histochem Cytochem* 1997;45:1715-22.

Jun HS, Kang Y, Notkins AL, Yoon JW. Gain or loss of diabetogenicity resulting from a single point mutation in recombinant encephalomyocarditis virus. *J Virol* 1997;71:9782-85.

Jun HS, Kang Y, Yoon HS, Kim KH, Notkins AL, Yoon JW. Determination of encephalomyocarditis viral diabetogenicity by a putative binding site of the viral capsid protein. *Diabetes* 1998;47:576-82.

Kearns-Jonker M, Sigounas G, Monell-Torrens E, Abbasi F, Holers VBM, Notkins AL. EBV binds to lymphocytes of transgenic mice that express the human CR2 gene. *Virus Res* 1997;50:85-94.

Kennedy T, Ghio AJ, Reed W, Samet J, Zagorski J, Quay J, Carter J, Dailey L, Hoidal JR, Devlin RB. Copper-dependent inflammation and NF- $\kappa$ B activation by particulate air pollution. *Am J Resp Crit Care Med* 1998, in press.

Kimura T, Zhang J, Sagawa K, Appella E, Siraganian RP. Syk independent tyrosine phosphorylation and association of the protein tyrosine phosphatases SHP-1 and SHP-2 with the high affinity IgE receptor. *J Immunol* 1997;159:4426-34.

Klier CM, Roble AG, Kolenbrander PE. *Actinomyces* serovar WVA963 coaggregation-defective mutant strain PK2407 secretes lactose-sensitive adhesin that binds to coaggregation partner *Streptococcus oralis* 34. Oral Microbiol Immunol 1998;13, in press.

Kolenbrander PE. Environmental sensing mechanisms and virulence factors of bacterial pathogens. In: Collier L, Balows A, Sussman M, eds. Topley and Wilson's Microbiology and Microbial Infections. 9<sup>th</sup> edition. London: Arnold Publishers 1998;9:307-26.

Kolenbrander PE, Andersen RN, Baker RA, Jenkinson HF. The adhesion-associated sca operon in *Streptococcus gordonii* encodes an inducible high-affinity ABC-transporter for Mn<sup>2+</sup> uptake. J Bacteriol 1998;180:290-95.

Kolenbrander PE. Biofilm developmental biology [Letter to the Editor]. Trends Microbiol 1997;5:475.

Koto H, Salmon M, Haddad EB, Huang TJ, Zagorski J, Chung KF. Role of cytokine-induced neutrophil chemoattractant (CINC) in ozone-induced airway inflammation and hyper-responsiveness. Am J Resp Crit Care Med 1997;156:234-39.

Latour S, Zhang J, Siraganian RP, Veillette A. A unique insert in the linker domain of Syk is necessary for its function in immunoreceptor signaling. EMBO J 1998;17:2584-95.

Leppla SH. Anthrax toxin lethal factor. In: Barrett AJ, Rawlings ND, Woessner JF, eds. Handbook of Proteolytic Toxins. New York: Academic Press 1998;1491-92.

Leiter EH, Tsumara H, Serreze DV, Chapman HD, Rabin DU, Lan MS, Notkins AL. Mapping to chromosomes 1 and 12 of mouse homologs of human protein tyrosine phosphatase, receptor-type, related genes encoding pancreatic  $\beta$  cell autoantigens. Mammal Gen 1997;8:949-50.

Li Q, Notkins AL, Lan MS. Molecular characterization of the promoter region of a neuroendocrine tumor marker, IA-1. Biochem Biophys Res Comm 1997;236:776-81.

London J, Kolenbrander PE. Coaggregation: Enhancing colonization in a fluctuating environment. In: Fletcher M, ed. Bacterial Adhesion: Molecular and Ecological Diversity. New York, NY: Wiley-Liss Inc. 1997;249-79.

Lu J, Li Q, Donadel G, Notkins AL, Lan MS. Profile and differential expression of protein tyrosine phosphatases in mouse pancreatic islet tumor cell lines. Pancreas 1997;16:515-20.

McCartney-Francis N, Wahl SM. TGF- $\beta$  and macrophages in the rise and fall of inflammation. Prog Inflamm Res 1998, in press.

McCartney-Francis N, Frazier-Jessen M, Wahl SM. TGF- $\beta$ : A balancing act. Intl Rev Immunol 1998;16:553-80.



McCartney-Francis NL, Mizel DE, Frazier-Jessen M, Kulkarni A, McCarthy J, Wahl SM. Lacrimal gland inflammation is responsible for ocular pathology in TGF- $\beta$ 1 null mice. *Am J Pathol* 1997;151:1281-88.

McCartney-Francis N, Song X-y, Mizel DE, Wahl CL, Wahl SM. Hemoglobin protects from streptococcal cell wall-induced arthritis. *Arthritis Rheum* 1998, in press.

Merkel TJ, Barros C, Stibitz S. Characterization of the *bvgR* gene of *Bordetella pertussis*. *J Bacteriol* 1998;180:1682-91.

Merkel TJ, Stibitz S, Keith JM, Leef M, Shahin R. Contribution of regulation by the *bvg* locus to respiratory infection of mice by *Bordetella pertussis*. *Infect Immun* 1998;66:4367-73.

Notkins AL, Lan MS, Leslie RDG. IA-2 and IA- $\beta$ : The immune response in IDDM. *Diabetes Metabolism Rev* 1998;14:85-93.

Notkins AL. Commentary: Intervention for diabetes prevention at neonatal age. *Diabetes Prevent* 1997;2:20.

Okazaki H, Zhang J, Hamawy MM, Siraganian RP. Activation of the protein tyrosine kinase Pyk2 is downstream of Syk in Fc $\epsilon$ RI signaling. *J Biol Chem* 1997;272:32443-47.

Orenstein JM, Wahl SM. The origin of HIV-infected multinucleated giant cells of hyperplastic tonsils and adenoids. *Am J Pathol* 1998, in press.

Pikis A, Donkersloot JA, Rodriguez WJ, Keith JM. A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in *Streptococcus pneumoniae*. *J Infect Dis* 1998;178:700-06.

Ryba NJP, Tirindelli R. Mammalian pheromone reception of mice and men? *NIH Catalyst*, 1998;6:8-10.

Sagawa K, Kimura T, Swieter M, Siraganian RP. The protein tyrosine phosphatase SHP-2 associates with tyrosine phosphorylated adhesion molecule PECAM-1 (CD31). *J Biol Chem* 1997;272:31086-91.

Sandkvist M, Michel LO, Hough LP, Morales VM, Bagdasarian M, Koomey M, DiRita VJ, Bagdasarian M. General secretion pathway (*eps*) genes required for toxin secretion and outer membrane biogenesis in *Vibrio cholerae*. *J Bacteriol* 1997;179:6994-7003.

Seissler J, Heine RJ, Scherbaum WA, de Sonnaville JJ, Morgenthaler NG, Steinnbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL. Immunological heterogeneity in type 1 diabetes: Presence of distinct auto-antibody patterns in patients with acute-onset and slowly progressive disease. *Diabetologia* 1998, in press.

- Shugars DC, Wahl SM. Role of the oral environment in HIV-1 transmission. *J Am Dent Assoc* 1998;129:851-58.
- Silver S, Wahl SM, Orkin B, Orenstein JM. Impact of ulcerative colitis on CD4 T cells and on tissue and circulating HIV: A case report. *Human Pathol* 1998, in press.
- Singh Y, Ivins BE, Leppla SH. Study of immunization against anthrax with the purified recombinant protective antigen of *Bacillus anthracis*. *Infect Immun* 1998;66:3447-48.
- Siraganian RP. Biochemical events in basophil/mast cell activation and mediator secretion. In: Kaplan AP, ed. *Allergy*, Second Edition. Philadelphia, PA: WB Saunders 1997;99-132.
- Siraganian RP. Basophils. In: Roitt IM, Delves PJ, eds. *Encyclopedia of Immunology*. Second Edition. London: WB Saunders 1998;332-34.
- Siraganian RP. Mast Cells. In: Roitt IM, Delves PJ, eds. *Encyclopedia of Immunology*. Second Edition. London: WB Saunders 1998;1667-71.
- Siraganian RP. Mechanism of IgE-mediated hypersensitivity. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, eds. *Allergy, Principals and Practice*. 5<sup>th</sup> edition. St. Louis, MO: Mosby-Year Book 1998;204-27.
- Siraganian RP, Zhang J, Kimura T. Regulation and function of protein tyrosine kinase Syk in FcεRI-mediated signaling. In: Razin E, Rivera J, eds. *Signal Transduction in the Activation of Mast Cells*. New York: Springer-Verlag New York Inc. 1998, in press.
- Siraganian RP. Signaling pathways that regulate effector function: perspectives. In: Razin E, Rivera J, eds. *Signal Transduction in the Activation of Mast Cells*. New York: Springer-Verlag New York Inc. 1998, in press.
- Siraganian RP: Mast cells and basophils. In: Kaliner MA, ed. *Current Review of Allergic Disease*. Philadelphia, PA: Current Medicine Inc. 1998, in press.
- Siraganian RP. Signal transduction from the high affinity IgE receptor. In: Gutkind SJ, ed. *Signal Transduction and Cell Cycle Inhibitors*. Totowa, NJ: The Humana Press Inc. 1998, in press.
- Skaleric U, Venkateshan C, Wahl SM. Superoxide release and cytopathogenic effects in gingival fibroblasts exposed to human immunodeficiency virus (HIV) and herpes simplex virus (HSV). *J Slov Med Soc* 1998;67:11.87-90.
- Skaleric U, Kramar B, Petelin M, Pavlica Z, Wahl SM. Changes in TGF-β1 levels in gingiva, crevicular fluid and serum associated with periodontal inflammation in humans and dogs. *Eur J Oral Science* 1997;105:136-42.



Smith PD, Wahl SM. Immunobiology of mucosal HIV-1 infection. In: Ogra P, Mestecky J, Lamm M, Strober W, McGhee J, Bienenstock J, eds. Mucosal Immunology. Second Edition. New York, NY: Academic Press 1998, in press.

Song X, Gu M, Jin W, Klinman D, Wahl SM. Plasmid DNA encoding transforming growth factor- $\beta$ 1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest 1998;101:2615-21.

Stephan V, Seibt A, Dukanovic D, Skasa M, Swaim WD, Berenstein EH, Siraganian RP, Wahn V. Anti-ganglioside monoclonal antibody AA4 selectively inhibits IgE-induced signal transduction pathways in rat basophilic leukemia cells. Mol Immunol 1997;34:227-35.

Takahashi Y, Sandberg AL, Ruhl S, Muller J, Cisar JO. A specific cell surface antigen of *Streptococcus gordonii* associated with bacterial hemagglutination and adhesion to  $\alpha$ 2-3-linked sialic acid-containing receptors. Infect Immun 1997;65:5042-51.

Tewari D, Notkins AL, Zhou P. Single-chain antibody to p17 expressed in T cells inhibits human immunodeficiency virus type 1 replication and results in defective virions. J Immunol 1998, in press.

Thompson J, Pikis A, Ruvinov SB, Henrissat B, Yamamoto H, Sekiguchi J. The gene *glvA* of *Bacillus subtilis* 168 encodes a metal-requiring, NAD(H)-dependent 6-phospho- $\alpha$ -glucosidase: Assignment to family 4 of the glycosylhydrolase superfamily. J Biol Chem 1998, in press.

Tirindelli R, Mucignat-Caretta C, Ryba NJP. Molecular aspects of pheromonal communication via the vomeronasal organ of mammals. Trends Neurosci 1998, in press.

Varughese M, Chi A, Teixeira AV, Nicholls PJ, Keith JM, Leppla SH. Internalization of a *Bacillus anthracis* protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol Med 1998;4:87-95.

Villarreal G, Zagorski J, Wahl SM. Acute inflammation. In: Encyclopedia of Life Sciences. London: Macmillan References Ltd. 1998, in press.

Wahl SM. Inflammation and growth factors. J Urol 1997;57:303-05.

Wahl SM. Transforming growth factor  $\beta$ . In: Gallin J, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. Third Edition. Philadelphia, PA: Lippincott-Raven Publishers 1998, in press.

Wahl SM, Greenwell-Wild T, Peng G, Hale-Donze H, Orenstein JM. Coinfection with opportunistic pathogens promotes HIV-1 infection in macrophages. J Infect Dis 1998, in press.

Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM, Janoff EN. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV. *Oral Diseases* 1997;3:564-69.

Wahl SM, Song X-y, Jin W, Lei KJ. Secretory leukocyte protease inhibitor (SLPI), not just a protease inhibitor. In: Guggenheim B, ed. *Oral Biology at the Turn of the Century: Misconceptions, Truths, Challenges and Prospects*. Basel, Switzerland: S Karger AG, 1998, in press.

Wahl SM, Wild TK, Sannenman TC, Janoff EN. Mucosal inhibitors of HIV-1. *J Slov Med Soc* 1998;67:11.91-94.

Wahl SM, McCartney-Francis N, Frazier-Jessen M, Feldman G, McCarthy JB. Integrins, inflammation, and intervention. *J Vasc Surg* 1998, in press.

Wahl SM, Greenwell-Wild T, Peng G, Hale-Donze H, Doherty TM, Orenstein JM. *Mycobacterium avium* complex (MAC) augments macrophage HIV-1 production and increases CCR5 expression. *Proc Natl Acad Sci* 1998, in press.

Wahl SM, Smith PD, Janoff EN. HIV-1 infection, mucosal immunity and pathogenesis. *J Infect Dis* 1998, in press.

Whittaker CJ, Kolenbrander PE. Identification and further characterization of a locus coding for a hypothetical 33.6 kDa protein involved in the intragenetic coaggregation of oral streptococci. *Adv Exp Med Biol* 1997;418:695-98.

Xie H, Deng J, Notkins AL, Lan MS. Expression, characterization, processing, and immunogenicity of an insulin-dependent diabetes mellitus autoantigen, IA-2, in SF-9 cells. *J Clin Exp Immun* 1998, in press.

Xie H, Zhang B, Matsumoto Y, Li Q, Notkins AL, Lan MS. Autoantibodies to IA-2 and IA-2 $\beta$  in IDDM recognize conformational epitopes: Location of the 37 and 40 kDa fragments determined. *J Immunol* 1997;159:3662-67.

Yamasaki Y, Matsuo Y, Zagorski J, Matsuura N, Onodera H, Itoyama Y, Kogure K. New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant in transient ischemic brain damage in rats. *Brain Res* 1997;759:103-11.

Yeung MK, Donkersloot JD, Cisar JO, Ragsdale PA. Identification of a gene involved in assembly of *Actinomyces naeslundii* T14V type 2 fimbriae. *Infect Immun* 1998;66:1482-91.

Zagorski J, Wahl SM. Inhibition of acute peritoneal inflammation in rats by a cytokine-induced neutrophil chemoattractant receptor antagonist. *J Immunol* 1997;159:1059-62.

Zagorski J, Wahl SM. Recruitment. In: Roitt IM, Delves PJ. eds. Encyclopedia of Immunology. Second Edition. London: Academic Press 1998, in press.

Zagorski J, Wahl SM. The accumulation of inflammatory mediators: A target for the prevention of fibrosis. In: Zella P, Greisher H, eds. Tissue Engineering of Prosthetic Vascular Grafts. New York, NY: Academic Press 1998;213-22.

Zhang J, Kimura T, Siraganian RP. Mutations in the activation loop tyrosines of protein tyrosine Syk abrogate intracellular signaling but not kinase activity. J Immunol 1998, in press.

Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: Targeting the endoplasmic reticulum and trans-golgi network. J Immunol 1998;160:1489-96.

# ORAL AND PHARYNGEAL CANCER BRANCH

*J. Silvio Gutkind*  
*Myung Hee Park*  
*Frank A. Robey*





## ORAL AND PHARYNGEAL CANCER BRANCH

### 1998

Cancer of the head and neck area is the sixth most common neoplastic disease in the developed world, representing a very serious health problem based on annual morbidity and mortality rates. The molecular and etiological factors involved in the development of head and neck tumors, including oral cancers, are still largely unknown. Members of our Branch work on several complementary aspects of cancer cell biology, in an effort to understand the molecular basis for malignant transformation as well as to use this knowledge to develop molecular markers of disease progression and novel therapeutic approaches for oral malignancies.

During the current reporting period, we have strategically initiated programs and recruited staff in areas which are relevant to oral cancer research. This includes the appointment of Dr. J. Silvio Gutkind as the Branch Chief, OPCB, the recruitment of Dr. Wendy Weinberg as a Staff Scientist to head a new workgroup focused on keratinocyte biology, and the expansion of Dr. Myung Hee Park, Dr. Frank Robey, and Dr. Gutkind's research programs, initiating several new projects in the areas of oral epithelial cell proliferation, differentiation, and neoplastic transformation. This new direction will afford us a better understanding of normal epithelial cell biology, and will likely broaden the horizon on developing potential oral tumor markers and treatments. Furthermore, our Branch has been playing a leading role in a newly formed NCI/NIDCR/NIDCD Inter-Institute Consortium in Head and Neck Cancer, whose goal is the development of a comprehensive clinical research program in head and neck cancer at the NIH, based on the interdisciplinary expertise of the intra- and extramural components of the three institutes.

Our Branch has been highly productive during this year: our annual report lists over 40 publications. We have made substantial contributions to the field, providing new concepts and shedding new light on questions of fundamental importance for cancer biology. We have also developed a large number of novel reagents, such as new genes, expression vectors, cell lines, antibodies, and bioactive peptides of value to biomedical research, and provided them to hundreds of investigators in the U.S. and abroad. Another tradition of our Branch has been our high priority on the training of postdoctoral investigators to become independent leaders in the field; we have tried to continue and strengthen this commitment. During the current reporting period, progress has been made in a number of research efforts at the OPCB. A variety of arbitrarily selected research advances are highlighted below. The progress report for each project provides a more comprehensive description of the major findings in our Branch.

We have recently initiated a new drug evaluation effort at the NIDCR, whose goal is to develop novel therapies aimed at improving the quality of life and life expectancy of oral cancer patients. As part of this project, we have recently evaluated newly identified drug candidates for their effectiveness in squamous cell carcinomas as a collaborative effort with the Developmental Therapeutic Program, NCI. It was found that one of the tested new drug candidates, flavopiridol, potently inhibits the proliferation of human squamous carcinoma cells and dramatically reduces tumor growth *in vivo*, thus establishing flavopiridol as a suitable drug candidate for treatment of head and neck carcinomas.

We have recently teamed up with other ICs to establish the Head and Neck Cancer Genome Anatomy Project, a collaborative joint effort with the NCI's Cancer Genome Anatomy Project. This involves the generation of cDNA libraries from squamous cell carcinoma lines and from microdissected cells derived from oral cancer tissues. After random sequencing, expressed genes are being catalogued and compared with those from normal corresponding tissues, and clones and data are being made available to qualified investigators through a new Web site. This work is expected to help identify gene products involved in the neoplastic process, as well as novel molecules representing clinically useful markers of oral carcinogenesis.

Acquired immunodeficiency syndrome-associated Kaposi's sarcoma (AIDS-KS) is the most common malignancy in human HIV infection. The oral cavity is frequently involved in AIDS-KS and may represent one of the most frequent initial sites of this malignancy. Kaposi's sarcoma associated herpesvirus (KSHV/ HHV 8) is a newly characterized  $\gamma$ -2 herpesvirus implicated in the pathogenesis of Kaposi's sarcoma. As part as a collaborative effort, we have recently found that a G protein-coupled receptor (GPCR) encoded by the open reading frame 74 of KSHV (KSHV-GPCR) displays constitutive (agonist-independent) activity, and is able to stimulate signaling cascades linked to cell proliferation and expression of angiogenic growth factors, such as VEGF.

Receptors coupled to heterotrimeric G proteins can effectively stimulate growth promoting pathways in a large variety of cell types, and if persistently activated, these receptors can also behave as dominant-acting oncoproteins. Consistently, activating mutations for G proteins of the  $G\alpha_s$  and  $G\alpha_{12}$  families have been recently found in human tumors; and we have shown that members of the  $G\alpha_q$  and  $G\alpha_{12}$  families are fully transforming when expressed in murine fibroblasts. In an effort aimed to elucidate the molecular events involved in proliferative signaling through heterotrimeric G proteins we have focused recently on gene expression regulation. We have recently demonstrated that G protein coupled receptors,  $G\alpha_{12}$  and the small GTP-binding protein RhoA are components of a novel signal transduction pathway that leads to the transcriptional activation of the *c-fos* Serum Response Element (SRE), and to cellular transformation. Furthermore, we have shown that a novel PDZ-domain containing guanine nucleotide exchange factor links heterotrimeric G proteins of the  $G\alpha_{12}$  family to Rho. In turn, the small GTP-binding proteins of the Rho family control a variety of biological activities, including organization of the actin cytoskeleton, regulation of gene expression and cellular transformation. Using effector loop mutants of Rho, we have recently established that cytoskeletal changes are not sufficient to induce the transformed phenotype, and that Rho-effector molecules regulating the actin cytostructure are distinct from those signaling to the nucleus and subverting normal growth control.

We have investigated the growth and differentiation properties of normal human gingival keratinocytes (NHGK) and found that the  $[Ca^{++}]$  optimum for culture and the squamous envelope composition of oral keratinocytes are different from those of normal human skin keratinocytes. We have also examined known markers of differentiation and found major differences in the expression of transglutaminase (TGase) I, TGase II and cytokeratins between NHGK and several head and neck cancer cell lines. In order to evaluate the roles of various proto-oncogenes and activated oncogenes in oral carcinogenesis, we introduced various oncogenes into immortalized



human gingival keratinocytes (IHGK). Immortalization of NHGK was accomplished by transfection with the pLXSN vector or the pBabe-Hygro vector carrying HPV16 E6/E7 genes, and immortalized cell lines were established after continued passage (>50) *in vitro*. IHGK express a similar pattern of cytokeratins as do NHGK and appear to retain the ability to induce TGase I and terminal differentiation after reaching post-confluence in media containing  $\text{Ca}^{++}$  at 0.15 mM. Various oncogenes implicated in head and neck squamous cell carcinomas (SCC) were individually transfected into IHGK. Oncogene-transfected cells were isolated and their growth and differentiation characteristics and tumorigenicity are currently under investigation.

Patients suffering from head and neck squamous cell carcinomas may have significant deficiencies in natural cellular and humoral immunity. Particularly, severe cellular immunosuppression can be detected early in the disease, and the cause of this is not clear yet. We have been building on our knowledge of immunosuppression caused by the envelope protein from HIV, gp120, as a template for studying HNSCC-induced immunosuppression. We have found that detergent extracts of solid tumors of HNSCC contain factors that are capable of binding to recombinant soluble CD4 in a fashion that is very closely related to the way gp120 binds to CD4. The same was found to be true of proteins secreted by cell cultures containing HNSCC. Studies using fluorescently labeled CD4 and HNSCC showed extensive labeling throughout the cells in culture and this indicates perhaps that natural proteins in the tumor, upon expression on the surface of the tumor or upon release from the tumor, can bind cell surface CD4 and induce CD4-mediated immunosuppression in T cells. Additionally, whether the HNSCC-derived proteins related to bone proteins such as osteopontin and BSP are involved in immunosuppression is a topic of investigation at the present time.

We have utilized keratinocytes of murine epidermis and both *in vitro* and *in vivo* approaches to dissect the stages of differentiation and neoplastic progression. Current efforts involve studies aimed at elucidating the function and mechanism of action of the p53 tumor suppressor gene product in keratinocyte biology and in squamous carcinogenesis. Particularly, we have explored the role of the WAF1 gene product in multistep carcinogenesis, and using both *in vivo* and *in vitro* models have demonstrated that loss of the p53 mediated gene WAF1 is not sufficient to explain the malignant phenotype of p53 null tumors; thus, other features of p53 beside transcriptional activation of the WAF1 gene are necessary for its tumor suppressor function.

With the assistance of our NIDCR Gene-targeting Core Facility, we have recently generated transgenic mice carrying the tetracycline-inducible system (*tet*-on receptor) targeted to the basal layer of stratified epithelium using the cytokeratin 5 promoter. Transgenes of interest, including candidate oncogenes, will be then expressed under the control of a tetracycline-responsive promoter, in a tetracycline dependent manner. Using this and other biologically relevant animal models, we are now positioned to test the transforming potential *in vivo* of activated alleles of a number of newly discovered signaling molecules, alone or upon co-expression with dominant interfering mutants of a variety of tumor suppressor genes.



## ORAL AND PHARYNGEAL CANCER BRANCH 1998 BIBLIOGRAPHY

- Alimandi M, Heidaran MA, Gutkind JS, Zhang J, Ellmore N, Kazalauskas VM, Pierce JH, Li Q. PLC- $\gamma$  activation is required for PDGF- $\beta$ R-mediated mitogenesis and monocytic differentiation in myeloid progenitor cells. *Oncogene* 1997;15:585-93.
- Andersen B, Weinberg WC, Rennekampff O, McEvilly RJ, Bermingham JR, Hooshmand F, Vasilyev V, Hansbrough JF, Pittelkow MR, Yuspa SH, Rosenfeld MG. Functions of the POU domain genes *Skn-1a/i* and *Tst-1* in epidermal differentiation. *Genes Dev* 1997;11:1873-84.
- Azzoli CG, Sagar M, Wu A, Lowry D, Hennings H, Morgan DL, and Weinberg WC. Cooperation of p53 loss of function and v-Ha-ras in transformation of mouse keratinocyte cell lines. *Mol Carcinog* 1998;21:50-61.
- Bais C, Santomaso B, Coso OA, Arvanitakis L, Raaka E, Gutkind JS, Asch A, Cesarman E, Gershengorn MC, Mesri E. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor is a viral oncogene and angiogenesis activator. *Nature* 1998;391:86-9.
- Bustelo XR, Crespo P, Lopez-Barahona M, Gutkind JS, Barbacid M. Cbl-b, a member of the sli-1/c-cbl protein family inhibits Vav-mediated c-Jun N-terminal kinase activation. *Oncogene*, 1997;15:2511-20.
- Cardinali M, Jakus J, Shah S, Ensley JF, Robbins KC, Yeudall WA. p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo. *Oral Oncol* 1998;34:211-8.
- Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA, Gutkind JS, Fusco A, Santoro M. Signaling of the Ret receptor tyrosine kinase through the JNK: evidence for a divergence of the ERKs and JNKs pathways induced by Ret. *Oncogene* 1998;16:2435-47.
- Crespo P, de Mora JF, Aaronson DS, Santos E, Gutkind JS. Transforming G protein-coupled receptors block insulin and ras-induced adipocytic differentiation in 3T3-L1 cells: Evidence for a PKC and MAP kinase independent pathway. *Biochem Biophys Res Commun* 1998;245:554-61.
- Deb TB, Wong L, Salomon DS, Zhou GC, Dixon JE, Gutkind JS, Thompson SA, Johnson GR. A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors - A specific role for SHP-2 in MAP, but not c-jun amino-terminal kinase activation. *J Biol Chem* 1998;273:16643-6.
- Fernandez-Salas E, Sagar M, Yuspa SH, Weinberg WC. A new gene encoding a chloride channel protein is regulated by the p53 and TNF-alpha pathways in keratinocytes. *Proc Am Assoc Cancer Research* 1998;39:27-8.

Fromm C, Coso OA, Montaner S, Xu N, Gutkind JS. The small GTP-binding protein Rho links G protein-coupled receptors and  $G_{\alpha_{12}}$  to the serum response element and to cellular transformation. *Proc Natl Acad Sci USA* 1997; 94:10098-103.

Grzesik WJ, Ivanov B, Robey FA, Southerland J, Yamauchi M. The interaction of periodontal ligament cells with conformationally constrained synthetic RGD peptides *in vitro*. *J Dental Res* 1998;76:377-84.

Gutkind JS, Coso OA, Xu N.  $G_{12}$  and  $G_{13}$   $\alpha$  Subunits of Heterotrimeric G Proteins: A Novel Family of Oncogenes. In: Spiegel AM, Humana Press, eds. *G Proteins, Receptors, and Disease*. 1998:101-17.

Gutkind JS. Cell Growth Control by G Protein-Coupled Receptors: from Signal Transduction to Signal Integration. *Oncogene*, in press.

Gutkind JS. Signaling from the Membrane to the Nucleus through Divergent MAP Kinase Cascades. In: Minden SA, Guttery P, eds. *Cell Signal Transduction, Implications for Drug Discovery*, IBC Library Series. 1998:39-60.

Gutkind JS. The pathway linking G protein-coupled receptors to divergent MAP kinase cascades. *J Biol Chem Minireview*, 1998;273:1839-42.

Igishi T, Gutkind JS. Tyrosine kinases of the Src family participate in signaling to MAP kinase from both  $G_q$  and  $G_i$ -coupled receptors. *Biochem Biophys Res Commun* 1998;244:5-10.

Jin D-Y, Teramoto H, Giam-Z, Chun RF, Gutkind JS, Jeang K-T. A human suppressor of JNK activation by  $TNF\alpha$ . *J Biol Chem* 1997;272:25816-23.

Joe YA, Wolff EC, Lee YB, Park MH. Enzyme-Substrate Intermediate at a Specific Lysine Residue is Required for Deoxyhypusine Synthesis: the Role of Lys329 in Human Deoxyhypusine Synthase. *J Biol Chem* 1997;272:32679-85.

Jones TLZ, Gutkind JS.  $G_{\alpha_{12}}$  requires acylation for its transforming activity. *Biochemistry* 1998;37:3196-202.

Lesaca EE, Ensley JF, Yeudall WA. Cellular factors may enable squamous carcinoma cells to overcome TGF beta-mediated repression of CDK2 activity. *Oral Oncol* 1998;34:52-7.

Liao D-I, Wolff EC, Park MH, Davies DR. Crystal structure of the NAD complex of human deoxyhypusine synthase: an enzyme with a ball and chain mechanism for blocking the active site. *Structure* 1998;6:23-32.

Liu JL, Blakesley VA, Gutkind JS, Le Roith D. The constitutively active mutant of  $G_{\alpha_{13}}$  transforms mouse fibroblast cells deficient in insulin-growth factor-I receptor. *J Biol Chem* 1997; 272:29438-41.

- Liu M, Zeng J, Robey FA. Specific interaction of conformational polypeptides derived from HIV gp120 with human T lymphocyte CD4 receptor. *Immunol Lett* 1998;63:1:27-32.
- Liu M-F, Zeng J, Robey FA. Tyrosine phosphorylation induced by C4 peptide constructs from HIV gp120. *Peptides International*, in press 1998.
- Lopez-Illasaca M, Gutkind JS, Wetzker R. Phosphoinositide 3-kinase  $\gamma$  is a mediator of  $G\beta\gamma$ -dependent Jun kinase activation. *J Biol Chem* 1998;273:2505-8.
- Murga C, Laguinge L, Wetzker R, Cuadrado A, Gutkind JS. Activation of Akt/PKB by G protein-coupled receptors: A role for  $\alpha$  and  $\beta\gamma$  subunits of heterotrimeric G proteins acting through PI3K $\gamma$ . *J Biol Chem* 1998;273:19080-85.
- Park MH, Joe YA, Kang KR. Deoxyhypusine synthase activity is essential for cell viability in the yeast *Saccharomyces cerevisiae*. *J Biol Chem* 1998;273:1677-83.
- Patel V, Jakus J, Harris CM, Ensley JF, Robbins KC, Yeudall WA. Altered expression and activity of G1/S cyclins and cyclin-dependent kinases characterize squamous cell carcinomas of the head and neck. *Int J Cancer*. 1997;73:551-5.
- Patel V, Senderowicz AM, Pinto D, Ensley J, Iguishi T, Sausville EA, Gutkind JS. Flavopiridol, a novel CDK inhibitor, suppresses the growth of squamous cell carcinomas by inducing apoptosis. *J Clin Invest*, in press.
- Rubino D, Driggers P, Arbit D, Kemp L, Miller B, Coso O, Pagliai K, Gray K, Gutkind JS, Segars J. Characterization of Brx, a novel DBL family member that modulates estrogen receptor action. *Oncogene* 1998;16:2513-26.
- Teramoto H, Gutkind JS. The pathway connecting muscarinic acetylcholine receptors to the nucleus involves small GTP-binding proteins. *Tanpakushitsu Kakusan Koso* 1998;43:35-41.
- Weinberg WC, Montano NE, Deng C. Loss of p21<sup>CIP1/WAF1</sup> does not recapitulate malignant conversion caused by p53 loss in experimental skin carcinogenesis. *Oncogene*, 1997;15:685-90.
- Weinberg WC, Yuspa SH. An antibody to p53 recognizes soluble keratins in epidermal keratinocyte cultures under differentiating, but not proliferating, conditions. *J Invest Dermatol* 1997;109:611-2.
- Winn DM, Diehl SR, Horowitz AM, Gutkind JS, Sandberg AN, Kleinman DV. Scientific progress in understanding oral and pharyngeal cancers. *J Amer Dental Assoc* 1998;129:713-8.
- Winn DM, Sandberg AN, Horowitz AM, Diehl SR, Gutkind JS, Kleinman DV. Reducing the burden of oral and pharyngeal cancers. *J Calif Dental Assoc*, in press.

Wolff, EC, Park, MH. Identification of Lys 350 in yeast deoxyhypusine synthase as the site of enzyme intermediate formation. *Yeast*, in press 1998.

Zohar M, Teramoto H, Katz B-Z, Yamada KM, and Gutkind JS. Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation. *Oncogene* 1998;17:991-8.





# PAIN AND NEUROSENSORY MECHANISMS BRANCH

*Raymond Dionne*

*Richard Gracely*

*Michael Iadarola*

*Daniel Kenshalo*

*Mitchell Max*

*M.A. Ruda*



## **PAIN AND NEUROSENSORY MECHANISMS BRANCH**

### **1998**

The Pain and Neurosensory Mechanisms Branch (PNMB) conducts a multidisciplinary research program aimed at improved understanding and treatment of pain. Studies range from evaluating molecular responses to tissue injury and elucidating the mechanisms of peripheral tissue inflammation, including subsequent changes within the nervous system, to evaluating novel drugs and clinical hypotheses about pain and its control in human models of acute and chronic pain. The hallmark of the Branch's research program is the integration of basic and clinical research which permits not only a rapid transfer of new findings from the laboratory to the clinic, but also fosters basic research based on clinical problems. This integrative approach provides an optimal environment for training clinicians and basic researchers in the principles and methods of pain research across a spectrum spanning basic molecular mechanisms to the clinical management of pain. In addition, the Branch's senior investigators participate widely in speaking, writing, and collaboration with professional organizations and academic institutions to transfer emerging scientific information to the training of clinicians and the treatment of patients.

The independence and challenge presented by the NIDCR reorganization and the opportunities for PI-initiated research have increased scientific vigor and productivity in the Branch. The mean number of publications per investigator (N=8) during fiscal year 1998, an indirect measure of scientific productivity, exceeds the number of publications per investigator during fiscal year 1995 (N=7), the last year under the old organizational structure. The Branch continues to operate a large clinical research program, the Pain Research Clinic, in the Magnuson Ambulatory Clinical Research Facility under the scientific direction of Drs. Max, Dionne and Gracely. Research conducted in this clinic is based on observations made in the Branch's basic laboratories as well as using novel and prototypic drugs to test emerging scientific hypotheses in man, representing a true 'bench to bedside' continuum. Numerous publications in respected peer-reviewed scientific journals attest to the Branch's continued scientific impact. Highlights of research findings by Branch investigators during the past year are presented below.

### **Selective Neurotoxins and Gene Transfer Mechanisms of Analgesia**

Demonstration of the internalization of the substance P receptor led to the hypothesis that this mechanism could interrupt pain transmission by selectively lesioning substance P receptor expressing cells in the spinal cord. Drs. Iadarola and Caudle coined the word "nocitoxins" to describe this concept of administering a ligand combining a toxin with substance P which when taken up into a SP secreting cell, results in cell death. They evaluated a compound composed of a substance P-diphtheria toxin fusion protein in the chronic constriction injury model. Administration of the fusion protein resulted in a partial, bilateral loss of SP receptor in the superficial dorsal horn which was accompanied by reduced mechanical and thermal hyperalgesia, but preserved normal nociceptive sensitivity in the side opposite the constriction injury and motor function in general, suggestive of selectivity for suppressing pathologic pain while maintaining normal protective sensory function.



Dr. Iadarola's lab also initiated an in vivo gene transfer program as a potential new means to treat chronic pain. Initial attempts with plasmids proved unsuccessful but direct infusion of adenoviral vectors was effective for transferring and expressing a reporter gene to spinal cord neurons and glial cells. The expression cassette is composed of a nerve growth factor leader sequence fused to beta-endorphin and is designed to secrete beta-endorphin. Injection of this vector into rat cerebrospinal fluid resulted in gene transfer to the cells covering the spinal cord and a substantial increase in cerebrospinal fluid beta-endorphin content. In an inflammation model of persistent pain, administration of the vector attenuated inflammatory hyperalgesia but had no effect on basal nociceptive responses. These data demonstrate a gene transfer approach to treatment of chronic pain disorders or cancer pain and will be further developed over the next year for possible clinical use.

### **Neonatal Persistent Pain Produces Plasticity in Nociceptive Neuronal Circuits**

Plasticity in the nervous system is increasingly recognized as a potential mechanism of chronic pain which persists after the initial stimulus or injury has been removed. Work in the Cellular Neuroscience Section this year provides insight into how this process may occur. Spinal nociceptive neural circuits develop during both embryonic and postnatal times when painful stimuli are normally absent or limited. Pain represents a unique stimulus when pathways are programmed to develop without nociceptive stimuli. A study conducted by Drs. Ruda and Ling examined the effect of early postnatal persistent pain on development of spinal pain pathways as a model for the effects of persistent pain on plasticity in the nervous system. On postnatal day one rats received an injection of complete Freund's adjuvant, a chronic irritant, unilaterally into a hindpaw followed by administration of a horseradish peroxidase conjugate at eight weeks of age as a marker for small diameter primary afferent nerve fibers. Spinal cord segments and dorsal root ganglion were later examined for labeling of these small diameter fibers in comparison to large myelinated fibers. Neonatal injection of the hindpaw resulted in a different pattern of staining in various laminae of the dorsal spinal cord as compared to the untreated paw. No difference was seen in labeling of the large unmyelinated axons in the right and left sciatic nerve. These data demonstrate a dramatic alteration in spinal pain pathways after neonatal persistent pain. This plasticity in nociceptive neuronal circuits may result in differences in the response to painful stimuli in the adult.

### **Imaging Pain Pathways in Humans**

The human functional brain imaging program conducted by Drs. Iadarola and Coghill continues to define the neural networks that subserve pain, the interaction between these networks, and the functional abnormalities induced by chronic pain in select pain populations. One study completed this year documents that acute pain induces a decrease in global cerebral blood flow that is likely attributable to activation of the sympathetic nervous system. This novel finding suggests a previously unidentified sympathetic regulation of the cerebral vasculature in acute pain/stress states and may explain pain-related syncope. A second investigation explored the relationship between painful heat stimuli, subjects' rating of pain intensity and unpleasantness, and regional brain activation. A significant relationship was observed between pain intensity and activation of a diverse array of brain regions providing a new level of insight into the

organization of brain mechanisms of pain processing. Two general schemes are evident: a distributed, parallel mechanism that is closely coupled with information about pain intensity, and a hierarchical mechanism involved in processes related to pain, but secondary to pain intensity. The distributed processing of pain intensity within the human brain ensures that this critical ability to detect tissue injury can be spared in the face of central nervous system damage while the hierarchical aspects of pain processing provide a basis for cognitive modulation of pain.

Another study conducted in collaboration with Dr. Gracely compared three qualitatively different pain sensations: pain evoked by brief painful heat stimulation of the skin, prolonged deep pain produced by exercising an ischemic limb, and the dysesthetic sensations that accompany reperfusion of the limb after 25 minutes of blood flow occlusion. The results showed a profound difference in the inferred patterns of supraspinal processing to these qualitatively different sensations. Brief heat pain sensations were accompanied by a large number of activations that have been observed in previous studies. The prolonged pain of ischemia resulted in fewer activations but with a marked increase in scalp blood flow by 20 minutes. The dysesthetic sensations were accompanied by a dramatic increase in activity in the somatosensory cortex, thalamus and insula. This result emphasizes the negative impact of dysesthesias, which are commonly observed in neuropathic pain conditions. The differences in activation with three equally painful conditions challenges the concept of a general pain-related pattern of supraspinal activity and suggests possible mechanisms which will be addressed in future studies.

### **Antihyperalgesic Effects of an AMPA/kainate Receptor Antagonist in Humans**

A study conducted by Dr. Max and colleagues in the past year involved the first reported administration of an antagonist for the AMPA/kainate receptor in humans. The study determined the maximally tolerated dose followed by a randomized, double-blind crossover study comparing the maximally tolerated dose, 1/3 the dose or placebo on capsaicin-evoked pain, mechanical hyperalgesia and allodynia. There was a dose-related reduction of pain, hyperalgesia and allodynia with the 1/3 maximally tolerated dose producing about a 50% reduction. While the maximally tolerated dose produced transient visual obscuration in most subjects, the lower dose was well tolerated. These data suggest possible clinical utility to developing this class of drugs in favor of other types of NMDA receptor antagonists that produce a high incidence of adverse effects along with their anti-hyperalgesic effects.

### **Postoperative Pain Contributes to the Development of Central Hyperalgesia in Humans**

It has been previously demonstrated in several clinical models that intraoperative nociceptive barrage contributes to the development of central hyperalgesia manifesting as increased clinical pain at later time points. A clinical study concluded this year evaluated the role of postoperative pain to the development of central hyperalgesia in humans. Subjects were randomly allocated to receive local anesthetic blockade of painful input either prior to oral surgery conducted under general anesthesia or prior to the onset of postoperative pain, both in comparison to placebo anesthetic. Blockade of the relatively brief duration of intraoperative nociceptive barrage could not be differentiated from patients receiving placebo. In contrast, blockade of postoperative nociceptive input significantly lowered the amount of pain reported at 48 hours, suggestive of

attenuation of the development of central hyperalgesia. These observations demonstrate the role of postoperative nociceptive input in the development of central hyperalgesia and suggest the need for preventive measures prior to pain onset to block pain during the postoperative period.

## **PAIN AND NEUROSENSORY MECHANISMS BRANCH 1998 BIBLIOGRAPHY**

Benoliel R, Eliav E, Mannes RJ, Caudle RM, Leeman S, Iadarola MJ. Actions of intrathecal diphtheria toxin-substance P fusion protein on models of persistent pain. *Pain*, in press.

Benoliel R, Tanaka M, Caudle RM, Iadarola MJ. Co-localization of NMDA receptors and substance P receptors in rat spinal cord. *Neurosci Lett*, in press.

Brennum J, Gracely RH. Measurement of clinical and experimental head pain. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. *The Headaches*, 2nd edition, Raven Press, in press.

Burbelo PD, Finegold AA, Kozak C, Yamada Y, Takami H. Cloning, genomic organization and chromosomal assignment of the mouse p190-B GTPase/Rho GAP gene. *Biochim Biophys Acta (Gene Structure and Expression)* 1998, in press.

Caudle RM, Mannes AJ, Iadarola MJ. GR89,696 is a Kappa2 opioid receptor agonist and a Kappa1 opioid receptor antagonist in the guinea pig hippocampus. *J Pharmacol Exp Ther* 1997; 283:1342-49.

Caudle RM, Mannes AJ, Tobias A, Finegold AA, Iadarola MJ. Spinal Kappa1 and Kappa2 opioid binding sites in rats, guinea pigs, monkeys and humans. *Neuroreport* 1998; 9:2523-25.

Chmielowska J, Coghill RC, Carson RE, Herscovitch P, Ishii K, Chen R, Hallett M. Comparison of PET [15O]water studies with 6-min and 10-min interscan intervals: Single subject and group analyses. *J Cereb Blood Flow Metab*, in press.

Chmielowska J, Coghill RC, Maisog JM, Carson RE, Herscovitch P, Honda M, Chen R, Hallett M. PET [15O]water studies with short interscan interval for single-subject and group analysis: Influence of background subtraction. *J Cereb Blood Flow Metab* 1998;18:433-44.

Chudler EH, Kenshalo DR. Supraspinal mechanisms of pain and nociception. In Bonica's *Management of Pain*, Loeser JD, ed. Media, PA:William and Wilkins 3rd edition, in press.

Coghill RC, Sang CN, Berman KF, Bennett GJ, Iadarola MJ. Global cerebral blood flow decreases during pain. *J Cereb Blood Flow Metab* 1998;18:141-47.

DeNucci D, Sobiski C, Dionne RA. Triazolam improves sleep but fails to alter pain in temporomandibular disorder patients. *J Orofac Pain* 1998;12:116-23.



Dionne RA. Evaluation of analgesic mechanisms and NSAIDs in the oral surgery model. In: Rainsford KD, Powanda MD, eds. *Safety and Efficacy of Non-Prescription (OTC) Analgesics and NSAIDs*. London:Kluwer Academic Publishers, 1998;105-17.

Dionne RA. Additive analgesic effects of oxycodone and ibuprofen in the oral surgery model. *J Oral Maxillofac Surg*, in press.

Dionne RA, Gordon SM, McCullagh LM, Phero JC. Assessment of clinical needs for anesthesia and sedation in the general population. *J Am Dent Assoc* 1998;129:167-73.

Dionne RA, McCullough L. Analgesic efficacy of the S(+) isomer of ibuprofen in comparison to racemic ibuprofen. *Clin Pharmacol Ther* 1998;63:694-701.

Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely R, Sethna N, MacLean DB. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. *Clin Pharmacol Ther* 1998; 64:562-68.

Dionne RA, Cooper SA. Use of ibuprofen in dentistry. In: Rainsford KD, ed. *Ibuprofen, A Critical Bibliographic Review*. London:Taylor & Francis, 1999, in press.

Dionne RA, Gordon SM, Tahara M, Rowan J, Troullos E. Analgesic efficacy and pharmacokinetics of ketoprofen administered into surgical extraction sites. *J Clin Pharmacol* 1999, in press.

Eliav E, Gracely RH. Sensory changes in the territory of the lingual and inferior alveolar nerves following lower third molar extraction. *Pain* 1998; 77:191-99.

Eliav E, Gracely RH. Trigeminal Neuralgia. In Block AR, Kremer E, Fernandez E, eds. *Handbook of Chronic Pain Syndromes*, Erlbaum and Associates, in press.

Gordon SM, Dionne RA, Snyder J. Dental fear and anxiety as a barrier to accessing oral health care among patients with special health care needs. *Spec Care Dent* 1998;18:88-92.

Gordon SM, Dubner R, Dionne RA. Antihyperalgesic effect of the N-methyl-D-aspartate antagonist dextromethorphan in the oral surgery model. *J Clin Pharmacol* 1999, in press.

Gracely RH. Persistent pain: Fell the tree or trim the branches? *Behav Brain Sci* 1997;20:449-51.

Gracely RH. Studies of pain in human subjects. In Wall PD, Melzack R, eds. *Textbook of Pain*, fourth edition, London:Churchill Livingstone, 1999, in press.

Harden RN, Rogers D, Fink K, Gracely RH. Controlled trial of ketorolac in tension-type headache. *Neurology* 1998;50:507-09.



Iadarola MJ, Caudle RM. Good pain, bad pain. *Science* 1997; 278: 239-40.

Iadarola MJ, Lee S, Mannes AJ. Gene transfer approaches for pain control. In: *Molecular Aspects of the Neurobiology of Pain*, Borsook D, ed. *Progress in Pain Research and Management*, Vol 9, Seattle:IASP Press, 1997;337-59.

Iadarola MJ, Berman KF, Zeffiro TA, Byas-Smith MG, Gracely RH, Max MB, Bennett GJ. Activation of multiple neural networks during acute pain and allodynia evoked by capsaicin assessed with positron emission tomography. *Brain* 1998;121:931-47.

Kenshalo DR Jr., Iwata K, Sholas M and Thomas DA. Response properties and organization of nociceptive neurons in primate SI cortex. *J Neurophysiol*, in press.

Kieburz K, Yiannoutsos C, Simpson D, Max MB, Clifford D. A controlled trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. *Neurology* 1999, in press.

Lenz FA, Gracely RH, Baker FH, Richardson RT, Dougherty PM. Modality reorganization of sensations evoked by microstimulation in the human thalamus in patients with pain following injuries to the nervous system. *J Comp Neurol* 1998;399:125-38.

Liu M, Max MB, Robinovitz E, Gracely RH, Bennett GJ. The human capsaicin model: sources of variability and methods of reduction. *J Pain Symptom Manage* 1998;16:10-20.

MacArthur L, Ren K, Pfaffenroth E, Franklin E, Ruda MA. Axons descending from the brainstem partially suppress spinal dynorphin mRNA and peptide up-regulation induced by peripheral inflammation and hyperalgesia. *Neuroscience*, in press.

Mannes AJ, Caudle RM, O'Connell BC, Iadarola MJ. Adenoviral transfer of LacZ to spinal cord neurons: intraparenchymal versus intrathecal administration. *Brain Res* 1998;793:1-6.

Max MB, Gilron I. Antidepressants, muscle relaxants, and some other drugs with central pain-relieving actions. In: Loeser JD ed., *Bonica's Management of Pain*, 3rd Ed. Baltimore:Williams & Wilkins, 1998, in press.

Max MB. Clinical trials of pain treatments. In: Portenoy RK, Bruera E, eds. *Research in Palliative Care: Methodologies & Outcomes*, 1998, in press.

Max MB, Portenoy RK. Pain research: Designing clinical trials for palliative care. In: Doyle D, Hanks GW, MacDonald N, eds. *Oxford Textbook of Palliative Medicine*. Oxford:Oxford University Press 1998;167-78.

Messersmith DJ, Kim DJ, Iadarola MJ. Transcription factor regulation of prodynorphin gene expression following rat hindpaw inflammation. *Mol Brain Res* 1998;53:260-70.

Naliboff BD, Munakata J, Fullerton S, Gracely R, Kodner A, Harraf F, Mayer EA. Evidence for two distinct perceptual alterations in visceral perception in irritable bowel syndrome. *Gut* 1997;41:505-12.

Sang CN, Hostetter MP, Gracely RH, Chappell A, Schoepp DD, Lee G, Whitcup S, Caruso R, Max MB. Effects of an AMPA/kainate antagonist in humans: reduction of hyperalgesia at subsedative doses. *Anesthesiology* 1998; 89:1060-67.

Sang CN, Max MB, Gracely RH. Cutaneous electrical stimulation to characterize mechanisms of allodynia: Validation and sources of variability. *J Pain Symptom Manage*, in press.

Sethna NF, Liu M, Gracely RH, Bennett GJ, Max MB. Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations vs. either drug alone after intradermal capsaicin in normal subjects. *Anesthesia Analgesia* 1998;86:1250-56.

Shlay J, Chaloner K, Max M, et. al. A randomized, placebo-controlled trial of a standardized acupuncture regimen or amitriptyline for pain caused by HIV-associated peripheral neuropathy. *J Am Med Assoc* 1998; 280:1590-95.

Smith WB, Gracely RH, Safer MA. The meaning of pain: cancer patients' rating and recall of pain intensity and affect. *Pain*, in press.

Sternberg WF, Bailin D, Grant M, Gracely RH. Competition alters perception of noxious heat and cold in male and female athletes. *Pain* 1998;76:231-38.

Treede RD, Kenshalo DR, Gracely RH and Jones AKP. The cortical representation of pain. *Pain*, in press.

Ward SE, Donovan M, Max MB. A survey of clinicians' perceptions of the impact of quality improvement programs on pain management. *J Pain Symptom Manage*, 1998;15:365-73.

Weiss SW, Dawson TM, Dawson VL, Iadarola MJ, Standaert DG. NMDAR1 glutamate receptor subunit isoforms in neostriatal, neocortical and hippocampal nitric oxide synthase neurons. *J Neurosci* 1998;18:1725-34.



# FUNCTIONAL GENOMICS UNIT

*Ashok Kulkarni*





## FUNCTIONAL GENOMICS UNIT

### 1998

Our Unit continues to generate exciting research advances in the pursuit of basic scientific knowledge in dissecting pathways relevant to the disorders that affect craniofacial and dental systems as a result of genetic abnormalities and inflammation. The Unit's primary research approach is centered on functional genomics. Since its inception, the key research work of the Unit has concentrated on the following studies:

#### **Molecular Genetics of Development**

In the first set of studies, we have begun to delineate precise roles of Cyclin dependent kinase-5 (Cdk5) in neuronal phosphorylation to gain insight into its role in abnormal phosphorylation observed in a number of neurodegenerative disorders. Following cloning of Cdk5 gene, we generated mice deficient in Cdk5 expression which exhibit perinatal mortality associated with gross lesions in the brains and spinal cords. Normal stratification of neocortical neurons in the cerebral cortex was absent in Cdk5(-/-) mice. These lesions included abnormal corticogenesis with a lack of neuronal, cerebellar defoliation, accumulation of neurofilaments in the neuronal cell bodies and ballooned motor neurons. Further studies revealed a typical inverted cortex in these mice indicating a special role of Cdk5 in neuronal migration. These findings prompt us to analyze in the future the key components of the neuronal cytoskeleton in the Cdk5 "conditional" knockouts.

In the second project, we chose to work on Fabry disorder because of its unique nature as a painful and fatal metabolic disorder and the challenges it presents in developing much needed therapeutic approaches. Following the cloning of the murine gene of alpha-galactosidase A, the gene involved in Fabry disease, we generated null which exhibit lipid inclusions in the target organs typically seen in Fabry patients. In collaboration with the Laboratory of Cell Biology in NCI, using gene therapy approaches we have demonstrated correction of the deficiency of enzymatic activity and the clearance of accumulated material in the cells derived from these mice. We are currently evaluating the progressive phenotypic changes in the older mice.

In the third project, we have begun to delineate the *in vivo* role of dentin sialophospho protein gene (dspp) in dentinogenesis. We have cloned and begun to characterize the structure, regulation and functions associated with the dspp gene products. We have developed a transgenic animal model with a reporter gene ( $\beta$ -galactosidase) under the control of 5.7 kb 5' flanking dspp sequences for further characterization.

#### **Molecular Genetics of Inflammation**

In this category of projects, we have begun to analyze the autocrine and endocrine roles of transforming growth factor beta-1 (TGF- $\beta$ 1) and macrophage migration inhibitory factor (MIF) in immune dysregulation and inflammation. The initial findings from studies indicate ameliorating effects of MHC-1 deficiency in inflammatory responses in the absence of TGF- $\beta$ 1 and also involvement of MIF beyond the immunology domain.

## FUNCTIONAL GENOMICS UNIT

### 1998 BIBLIOGRAPHY

- Wahl SM, Kulkarni AB. TGF- $\beta$ : an anti-inflammatory cytokine in vitro and in vivo. In: Handbook of Experimental Immunology 5th edition. New York:Blackwell Scientific; 1997:222.1-222.
- Kulkarni AB, Letterio JJ. TGF- $\beta$ 1 knockout mouse: The phenotype and its implications for TGF- $\beta$ 1 isoform. In: Durum S., Muegge K. Cytokine Knockouts, Totowa, NJ:Humana Press; 1997:369-400.
- Kulkarni AB, Karlsson S. Inflammation and TGF beta 1: lessons from the TGF beta 1 null mouse. Immunology 1997;148: 453-6
- Ohshima T, Murray, GJ, Swaim WD, Longenecker G, Quirk J, Cardarelli, CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB. Alpha-Galactosidase A deficient mice: A model of Fabry disease. Proc Natl Acad Sci USA 1997;94: 2540-44.
- D'Souza RN, Cavender A, Sunavala G, Alvarez J, Ohshima T, Kulkarni AB, MacDougall M. Gene expression patterns of murine dentin matrix protein 1(Dmp1) and dentin sialoprotein (DSPP) suggest distinct developmental functions in vivo. J Bone Min Res 1997;12:2040-9.
- Feng JQ, Luan X, Wallace J, Jing D, Ohshima T, Kulkarni AB, D'Souza RN, Kozak CA, MacDougall M. Genomic organization, chromosomal mapping, and promoter analysis of the mouse DSPP gene, which codes for both dentin sialoprotein and dentin phosphoprotein. J Biol Chem 1998;273:9457-64.
- Sudarshan C, Yaswen L, Kulkarni AB, Raghov R. Cell cycle changes and phenotypic consequences of transforming growth factor-  $\beta$ 1 gene ablation in murine embryonic fibroblasts. Autocrine control of cell cycle and extracellular matrix. J Cell Physiol 1998;176:67-75.
- Kobayashi S, Yoshida K, Ohshima T, Esumi N, Paralkar VM, Wistow G J, Kulkarni AB. DNA sequence motifs are associated with aberrant homologous recombination in the mouse macrophage migration inhibitory factor (MIF) locus. Gene 1998;15:85-92.
- Gilmore EC, Ohshima T, Goffinet AM, Kulkarni AB, Herrup K. Cdk5 deficient mice demonstrate novel developmental arrest in cerebral cortex. J Neurosci 1998;18:6370-77.
- Xu T, Longenecker G, Fisher L, Heegaard AM, Satomura K, Bianco P, Sommer B, Kulkarni AB, Robey PG, Young, M. Targeted disruption of the biglycan gene leads to an osteoporotic-like phenotype in mice. Nature Genet 1998;20:78-82.

# IMMUNOPATHOLOGY SECTION

*Larry Wahl*





## IMMUNOPATHOLOGY SECTION

1998

The focus of the Immunopathology Section is on defining the factors and signal transduction pathways involved in the modulation of human monocyte functions that may contribute to the immunopathology associated with various disease states. Connective tissue destruction is associated with many diseases in which the monocyte/macrophage is a prominent cell. A major emphasis has been placed on how matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) are regulated, since these enzymes and inhibitors are believed to play a major role in the destruction and remodeling of connective tissue.

### **Cytokine regulation of monocyte MMPs and TIMP-1**

We have shown that the individual addition of TNF $\alpha$ , GM-CSF, or IL-1 $\beta$  to monocytes enhanced MMP-9 and TIMP-1 but failed to induce MMP-1. However, when these cytokines were added together, particularly TNF $\alpha$  and GM-CSF, they stimulated the synthesis of MMP-1 and synergistically enhanced MMP-9 and TIMP-1. IFN- $\gamma$  has been shown to inhibit MMP production by Con A or LPS activated monocytes but the effect of this cytokine on these mediators differs in the presence of other cytokines. IFN- $\gamma$  inhibited the enhancement of MMP-9 and TIMP-1 by TNF $\alpha$  or IL-1 $\beta$ , but increased GM-CSF induced levels of MMP-9. Moreover, GM-CSF blocked the ability of IFN- $\gamma$  to inhibit TNF $\alpha$  or IL-1 $\beta$  induced MMP-9. Of particular interest was the induction of MMP-1 when IFN- $\gamma$  was combined with GM-CSF. IFN- $\gamma$  also enhanced MMP-1 production induced by the combination of GM-CSF and TNF $\alpha$  but decreased MMP-9 and TIMP-1. These results indicate that regulation of monocyte MMPs and TIMP-1 at an inflammatory site is complex and depends, in part, on the specific cytokines present.

### **Signaling pathways involved in the differential regulation of monocyte MMPs**

Our recent studies on the signal transduction pathway leading to MMP production by LPS stimulated monocytes have revealed that p42 MAP kinase is predominately involved in the regulation of MMP-9 whereas MMP-1 and prostaglandin H synthase-2 are mainly controlled by p38 MAP kinase. Inhibition of p38 MAP kinase activity significantly reduced the LPS-induced MMP-1 and phosphorylation of AP-1, CREB, and NF $\kappa$ B. This inhibition was reversed by the addition of PGE<sub>2</sub>, a known modulator of monocyte MMPs. However, inhibition of p42 MAP kinase activity did not block LPS-mediated activation of AP-1 and CREB, but did irreversibly suppress the phosphorylation of NF $\kappa$ B. Taken together, these findings indicate that p42 MAP kinase activation appears to be linked to the preferential regulation of MMP-9 through NF $\kappa$ B, whereas the phosphorylation of AP-1 and CREB by p38 MAP kinase is involved in the regulation of monocyte MMP-1 and prostaglandin H synthase-2.

### **Monocyte MT1-MMP**

The recently described membrane-type metalloproteinases (MT-MMPs) form a family of membrane-bound enzymes that have as one of their functions the activation of MMP-2 (gelatinase A). We have shown that activation of monocytes results in the induction of MT1-

MMP mRNA and protein through a prostaglandin dependent mechanism. Monocyte MT1-MMP activated the MMP-2 produced by human marrow stromal cells and some cancer cell lines. These findings suggest that the MT1-MMP expressed on monocytes may have an important role in bone metabolism and in cancer progression.

## **IMMUNOPATHOLOGY SECTION 1998 BIBLIOGRAPHY**

Shankavaram, UT, DeWitt DL, Funk SL, Sage EH, Wahl LM. Regulation of human monocyte matrix metalloproteinases by SPARC. *J Cell Physiol* 1997;173:327-34.

Egidy G, Friedman J, Viswanathan M, Wahl LM, Saavedra JM. CGP 42112 suppresses lipopolysaccharide stimulation of TNF- $\alpha$ , IL-1, IL-6 and matrix metalloprotease-9 in human monocytes. *Am J Physiol* 1997;273:C826-33.

Pollack M, Ohl CA, Golenbock DT, Di Padova F, Wahl LM, Koles NL, Guelde G, Monks BG. Dual effects of lipopolysaccharide (LPS) antibodies on cellular uptake of LPS and LPS-induced proinflammatory functions. *J Immunol* 1997;159:3519-30.

Wahl LM, Shankavaram UT, Zhang Y. Role of macrophages in vascular tissue remodeling. *Transp Immunol* 1997;5:173-76.

Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. *J Immunol* 1997;159:4077-83.

Zhang Y, McCluskey K, Fujii K, Wahl LM. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF $\alpha$ , GM-CSF, and IL-1 $\beta$  through prostaglandin dependent and independent mechanisms. *J Immunol* 1998;161:3071-76.

Shankavaram UT, DeWitt DL, Wahl LM. Lipopolysaccharide induction of monocyte matrix metalloproteinases is regulated by tyrosine phosphorylation of cytosolic phospholipase A<sub>2</sub>. *J Leuk Biol* 1998;64:221-27.

Karp CL, Wysocka M, Ma X, Marovich M, Factor RE, Nutman T, Armant M, Wahl L, Cuomo P, Trinchieri G. Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. *Eur J Immunol* 1998;28:1-9.

Wahl LM, Kleinman HK. Tumor associated macrophages as targets for cancer therapy. *J Natl Cancer Inst* 1998, in press.

# MATRIX METALLOPROTEINASE UNIT

*Henning Birkedal-Hansen*





## MATRIX METALLOPROTEINASE UNIT

### 1998

The research of the Matrix Metalloproteinase Unit explores mechanisms which enable cells to dissolve and degrade the extracellular matrix. Specifically we are seeking to define the role of matrix metalloproteinases (MMPs) and their inhibitors in this process.

A body of evidence suggests that MT1-MMP, TIMP-2 and Gelatinase A play important roles in mediating or regulating collagen degradation. Using gene targeting approaches we observed that disruption of the MT1-MMP gene resulted in a severe skeletal and soft tissue phenotype indicative of major defects in extracellular matrix metabolism including dwarfism, severe runting, osteopenia, deficient enchondral and intramembraneous bone formation, abnormal craniofacial development, and premature death. The MT1-MMP phenotype is the most severe of any MMP “knock-out.” Disruption of the TIMP-2 gene by deletion of exons 2 and 3 gave rise to seemingly minor phenotypic changes, but further analysis unveiled significant and profound differences between wildtype and mutant mice. In a murine mammary tumor virus (MMTV) model, TIMP-2 mutant mice had the essentially the same tumor burden but much lower levels of (spontaneous) lung metastasis than wildtype mice. We also noticed that while Gelatinase A is partially activated in extracts of normal lungs, comparable extracts from homozygous TIMP-2 mutant mice contain Gelatinase A in its pro-enzyme form, lending the first in vivo support for the MT1-MMP activation of Gelatinase A through TIMP-2 bridging.

In search of enzymes and inhibitors which regulate and catalyze the metabolic degradation of extracellular matrix, we pursued a strategy which allowed us to monitor the dissolution of a proteolytically resistant, single-component matrix (collagen type I fibrils) by live cells. Using this model, we examined the function of MT1-MMP and TIMP-2 deficient mice using cells derived from homozygous mutant mice. Cells deficient in MT1-MMP show greatly reduced ability to activate Gelatinase A and to dissolve collagen fibrils. Cells derived from TIMP-2 deficient mice showed reduced ability to activate Gelatinase A (MMP-2) and failed to degrade collagen fibrils in some model systems, lending support to the notion that (at least some) pathways leading to dissolution of collagen fibrils are mediated by a TIMP-2/Gelatinase A-dependent mechanism. Transfection experiments further confirmed the requirement for both MT1-MMP and Gelatinase A for expression of a collagen-degrading phenotype.

To better understand MMP activation reactions at the molecular level, we also explored the function of the “Cysteine Switch.” The switch is the structural and molecular basis for catalytic latency and activation of MMPs. Using a site-directed mutagenesis approach, we learned that the propeptide is held in place in its docked position by coordinate bonding to the active site Zn (Cys-Zn bond) and by a number of secondary molecular interactions along the propeptide. Disruption of either of these, by any of a number of disparate means, results in displacement of the propeptide and opens up access to the active site (i.e. activation).

The MMP unit also conducted studies on enamelysin (MMP-20) which appears to be the only MMP specific for tooth development. During the past year we isolated, and completed the characterization of, the 65 kilobase mouse enamelysin gene. A targeting vector for disruption of

the gene by homologous recombination has been constructed and chimeric mice generated. These studies are being conducted in collaboration with Dr. John Bartlett (Forsyth Dental Center, Boston, MA) and Dr. James Simmer (University of Texas Health Science Center, San Antonio, TX).

## **MATRIX METALLOPROTEINASE UNIT 1998 BIBLIOGRAPHY**

Caterina NCM, Windsor LJ, Yermovsky AE, Bodden MK, Taylor KB, Birkedal-Hansen H, Engler JA. Replacement of conserved cysteines in human TIMP-1 (Tissue inhibitor of metalloproteinases-1). *J Biol Chem* 1997;272:32141-49.

Havemose-Poulsen A, Holmstrup P, Stolze K, Birkedal-Hansen H. Dissolution of type I collagen fibrils by gingival fibroblasts isolated from patients of various periodontitis categories. *J Periodont Res* 1998;33:280-91.

Caterina NCM, Windsor LJ, Bodden MK, Yermovsky AE, Taylor KB, Birkedal-Hansen H, Engler JA. Glycosylation and NH<sub>2</sub>-terminal domain mutants of the tissue inhibitor metalloproteinases-1 (TIMP-1). *Biochim Biophys Acta* 1998;21-34.

DeCarlo AA, Grenett HE, Harber GJ, Windsor LJ, Bodden ML, Birkedal-Hansen B, Birkedal-Hansen H. Induction of matrix metalloproteinases and a collagen-degrading phenotype in fibroblasts and epithelial cells by secreted *Porphyromonas gingivalis* proteinase. *J Periodont Res* 1998;33: 408-20.

Birkedal-Hansen H. Links between microbial colonization, inflammatory response and tissue destruction. In: Guggenheim B, ed. *Proceedings of the European Research Group in Oral Biology International Research Conference: "Oral Biology at the Turn of the Century: Misconceptions, Truths, Challenges and Prospects"*, in press.

Birkedal-Hansen H, Caterina NC, Bodden MK, Windsor LJ, Birkedal-Hansen B, Engler JA. TIMP: Structure Function Relationships. *Proceedings of: Inhibitors of Metalloproteinases in Development and Disease: TIMP '96*, in press

Galazka G, Windsor LJ, Birkedal-Hansen H, Engler JA. Spontaneous propeptide processing of mini-stromelysin-1 mutants blocked by APMA (4-aminophenylmercuric acetate). *Biochemistry*, in press

# MOLECULAR STRUCTURAL BIOLOGY UNIT

*Dennis Torchia*





## **MOLECULAR STRUCTURAL BIOLOGY UNIT**

### **1998**

The principal research goal of the Molecular Structural Biology Unit (MSB) is to elucidate the structure and dynamics of proteins, RNAs and associated molecules at the atomic level in order to provide a basis for understanding function. The main research tool used in this work is high resolution multidimensional nuclear magnetic resonance (NMR) spectroscopy. Three projects are currently active: (1) HIV-1 protease, as either the free enzyme or bound to a high affinity protease inhibitor; (2) the RNA binding protein S4, either free or bound to a target RNA molecule; (3) MAP-30, an anti HIV protein. Following is a summary of the progress the MSB has been made in characterizing the molecular structure and dynamics of these systems as well as the prospective research for the coming year.

#### **HIV-1 protease**

The molecular dynamics of a fully active, but stable protease mutant (Q7K, L33I, L63I) has been studied in order to understand how substrates and inhibitors are able to enter and exit the protein's active site. Novel relaxation experiments developed in the past year in the Unit show that residues G48 through I54 (in the flaps of the protein) undergo slow conformation exchange. We suggest that these slow motions reflect the dynamic equilibrium between the semi-open and fully open flap conformations. It is these slow conformational fluctuations of the protease flaps that permit entry and exit of substrates, products and inhibitors from the active site of the protein. The goal of future work is to characterize the dynamics of the protein side chains that make up the substrate/inhibitor binding site of the protease.

#### **Structures of the ribosomal proteins S4-d41 and S4**

We have solved the solution structure of S4-d41, the C-terminal domain of the RNA binding ribosomal protein S4 (S4-d41, 159 residues, S4, 200 residues). The relative orientation of the subdomains of S4-41 is loosely defined, and because the likely RNA binding site consists of side chains from each subdomain, relative flexibility of the subdomains could explain how the protein binds to two very distinct RNA target molecules. However, limited NOESY data could limit the precision of the solution structure. Therefore, we are measuring dipolar couplings to better determine the relative orientation of the subdomains of S4-d41 in solution. We have also begun work on determining the structure of intact S4, which binds to mRNA about ten-fold better than S4-d41. Our goal will be to determine how the N-terminal 41 residues affect (a) the structure of the protein and (b) its binding to its target mRNA.

#### **Structure/function study of the anti-HIV protein, Map30**

Using multidimensional NMR methods, we have obtained nearly complete signal assignments of this 263-residue protein. Based upon these assignments, ca. 4000 distance, angle restraints and dipolar restraints have been used to derive the solution structure of the protein. Comparison of the backbone coordinates of the average MAP30 solution structure and crystal structures of homologous proteins Ricin A, tyrosanthin, byrodin and momordin show that all these proteins

have very similar overall structures. This observation raises the question as to how MAP30 can have several distinct activities not shared by ricin A and other RIPs. Preliminary results suggest that the anti-HIV integrase activity reported for MAP30 results from MAP30 binding to DNA substrates, rather than from a direct interaction with integrase.

The PI was invited to speak at the 27'th International Conference on NMR in Biological Systems in Tokyo, and serves as Associate Editor of PROTEINS. The PI participated as a major reviewer on the site visit of the NMR facility of the National Magnetic Lab, reviews ca. 50 proposals/scientific papers per year and maintains research collaborations with researchers in major institutions in this country and abroad. He was appointed to the SBRS in 2/98.

## **MOLECULAR STRUCTURAL BIOLOGY 1998 BIBLIOGRAPHY**

Hinck AP, Markus MA, Huang S, Grzesiek S, Kustanovich I, Draper DE, Torchia DA. The RNA binding domain of ribosomal protein L11: Three-dimensional structure of the RNA bound form of the protein and its interaction with 23S rRNA. *J Mol Biol* 1997;274:101-13.

Copie V, Tomita Y, Akiyama SK, Aota S, Yamada KM, Venable RM, Pastor RW, Krueger S, Torchia DA. Solution structure and dynamics of linked cell attachment modules of mouse fibronectin containing the RGD and synergy regions: comparison with the human fibronectin crystal structure. *J Mol Biol* 1998;277:663-82.

Freedberg DI, Wang YX, Stahl SJ, Kaufman JD, Wingfield PT, Kiso Y, Torchia DA. Flexibility and function in HIV Protease: dynamics of the HIV-1 protease bound to the asymmetric inhibitor kynostatin 272 (KNI-272). *J Am Chem Soc* 1998;120:7916-23.

Wang YX, Marquardt JL, Wingfield P, Stahl SJ, Lee-Huang S, Torchia DA, Bax A. Simultaneous measurement of  $^1\text{H}$ - $^{15}\text{N}$ ,  $^1\text{H}$ - $^{13}\text{C}'$ , and  $^{15}\text{N}$ - $^{13}\text{C}'$  dipolar couplings in a perdeuterated 30 kDa protein dissolved in a dilute liquid crystalline phase. *J Am Chem Soc* 1998;120:73859-60.

Markus MA, Torchia DA, Gerstner RB, Draper DE. The solution structure of ribosomal protein S4 delta41 reveals two subdomains and a positively charged surface that may interact with RNA. *EMBO J* 1998;17:in press.

Ishima R, Wingfield PT, Stahl SJ, Kaufman JD, Torchia DA. Using amide  $^1\text{H}$  and  $^{15}\text{N}$  transverse relaxation to detect millisecond time-scale motion in perdeuterated proteins: application to HIV-1 protease. *J Am Chem Soc* 1998;120: 10534-42.

Ishima R, Louis JM, Torchia DA. Transverse  $^1\text{H}$  cross relaxation in  $^1\text{H}$ - $^{15}\text{N}$  correlated  $^1\text{H}$  CPMG experiments. *J Magn Reson* 1999, in press.





